Consolidated Financial Statements June 30, 2017 and 2016 (With Independent Auditors' Report Thereon)

SAINT LOUIS UNIVERSITY
Consolidated Financial Statements
June 30, 2017 and 2016
(With Independent Auditors’ Report Thereon)

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
AS OF JUNE 30,
(000’s omitted)
Assets 2017 2016

Cash and cash equivalents $ 80,851 $ 34,387
Accounts receivable, net 87,322 98,892
Prepaid expenses 5,738 5,013
Investments 1,221,818 1,141,542
Notes receivable 32,898 33,588
Unexpended bond proceeds 12,494 9,252
Funds held by trustees 59,117 54,440
Land, buildings, and equipment, net 683,448 632,948
Other assets 85,055 85,586
Total assets $ 2,268,741 $ 2,095,648
Liabilities and Net Assets
Accounts payable $ 41,684 $ 30,321
Accrued payroll and benefits 47,462 50,259
Deposits and deferred revenues 43,054 35,932
Other accrued liabilities 79,609 95,005
Notes and bonds payable 411,052 340,214
U.S. government refundable grants 22,420 24,330
Total liabilities 645,281 576,061
Net assets:
Unrestricted 1,174,749 1,105,243
Temporarily restricted 139,640 116,582
Permanently restricted 309,071 297,762
Total net assets 1,623,460 1,519,587
Total liabilities and net assets $ 2,268,741 $ 2,095,648
See Accompanying Notes to the Consolidated Financial Statements
3
CONSOLIDATED STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2017
(000’s omitted)
Temporarily Permanently June 30, 2017

Unrestricted restricted restricted Total
Operating revenues and other support:
Education and related activities:
Tuition and fees, gross $ 420,364 $ 420,364
Less scholarship allowances (151,214) (151,214)
Tuition and fees, net 269,150 269,150
Government grants and contracts 35,097 35,097
Contributions and private grants 27,252 $ 2,487 29,739
Endowment and other investment income 55,496 55,496
Auxiliary enterprises 51,996 51,996
Other 16,740 16,740
Total education and related activities 455,731 2,487 458,218
Patient care:
Patient care (net of contractual allowances and discounts) 354,135 354,135
Less provision for bad debts (12,666) (12,666)
Net patient care less provision for bad debts 341,469 341,469
Net assets released from restrictions 2,493 (2,493) —
Total operating revenues and other support 799,693 (6) 799,687
Operating expenses:
Salaries and benefits 567,218 567,218
Supplies, repairs, utilities, and other expenses 190,185 190,185
Depreciation and amortization 37,969 37,969
Interest expense 13,554 13,554
Total operating expenses 808,926 808,926
Net operating results (9,233) (6) (9,239)
Nonoperating:
Investment return net of amounts designated for operations 79,040 23,180 $ 2,033 104,253
Permanently restricted contributions and private grants 7,155 7,155
Other, net (301) (116) 2,121 1,704
Total nonoperating, net 78,739 23,064 11,309 113,112
Change in net assets 69,506 23,058 11,309 103,873
Net assets at beginning of year 1,105,243 116,582 297,762 1,519,587
Net assets at end of year $ 1,174,749 $ 139,640 $ 309,071 $ 1,623,460
4
CONSOLIDATED STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2016
(000’s omitted)
Temporarily Permanently June 30, 2016

Operating revenues and other support:
Tuition and fees, gross $ 404,875 $ 404,875
Less scholarship allowances (139,373) (139,373)
Tuition and fees, net 265,502 265,502
Government grants and contracts 33,326 33,326
Contributions and private grants 25,609 $ 1,421 27,030
Endowment and other investment income 55,400 55,400
Other 15,332 15,332
Total education and related activities 445,722 1,421 447,143
Patient care:
Patient care (net of contractual allowances and discounts) 335,335 335,335
Less provision for bad debts (10,724) (10,724)
Net patient care less provision for bad debts 324,611 324,611
Net assets released from restrictions 7,491 (7,491) —
Total operating revenues and other support 777,824 (6,070) 771,754
Operating expenses:
Salaries and benefits 560,459 560,459
Supplies, repairs, utilities, and other expenses 181,512 181,512
Interest expense 10,543 10,543
Total operating expenses 788,479 788,479
Net operating results (10,655) (6,070) (16,725)
Nonoperating:
Investment return net of amounts designated for operations (66,733) (19,800) $ 420 (86,113)
Other, net (7,840) (84) 124 (7,800)
Total nonoperating, net (74,573) (19,884) 5,599 (88,858)
Change in net assets (85,228) (25,954) 5,599 (105,583)
Net assets at beginning of year 1,190,471 142,536 292,163 1,625,170
Net assets at end of year $ 1,105,243 $ 116,582 $ 297,762 $ 1,519,587
5
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED JUNE 30,
(000’s omitted)
2017 2016
Net cash flows from operating activities:
Increase / (decrease) in net assets $ 103,873 $ (105,583)
Adjustments to reconcile change in net assets:
Net (gains) / losses on disposition of property and equipment 1,629 (270)
(Increase) / decrease in accounts receivable, net 12,809 (13,368)
Increase / (decrease) in accounts payable 6,253 349
Increase / (decrease) in accrued payroll and benefits (5,934) 2,625
Increase / (decrease) in deposits and deferred revenues 7,122 6,026
Increase / (decrease) in other accrued liabilities 1,371 7,315
(Increase) / decrease in other assets 531 (445)
Other changes in assets and liabilities (2,834) 5,961
Contributions restricted for permanent endowment (8,228) (5,199)
Contributions restricted for acquisitions of property and equipment (185) (152)
Investment income restricted for long-term investment (506) (453)
Net (gains) / losses on long-term investments (142,452) 47,200
Net (gains) / losses on assets held by trustees (1,261) 1,923
Net cash provided by (used in) operating activities 10,157 (18,106)
Net cash flows from investing activities:
Proceeds from sales and maturities of investments 610,018 468,323
Purchases of investments (567,861) (439,841)
Proceeds from sale of property and equipment 6,316 442
(Increase) / decrease in assets held by trustees, excluding net gains and losses (269) —
Investment in SSM Health Care St. Louis — (47,773)
Purchases of property and equipment (98,210) (80,708)
Net cash used in investing activities (50,006) (99,557)
Net cash flows from financing activities:
Issuance of notes receivable (3,175) (1,865)
Payments on notes receivable 3,862 4,401
Issuance of notes and bonds payable 151,180 145,020
Payments on notes and bonds payable (80,525) (52,759)
Increase / (decrease) in cash overdrafts 7,291 (2,614)
Contributions restricted for permanent endowment 6,986 5,338
Contributions restricted for acquisitions of property and equipment 188 152
Investment income restricted for long-term investment 506 453
Net cash provided by financing activities 86,313 98,126
Net increase (decrease) cash and cash equivalents 46,464 (19,537)
Cash and cash equivalents, beginning of year 34,387 53,924
Cash and cash equivalents, end of year $ 80,851 $ 34,387
Supplemental data:
Interest paid $ 13,558 $ 10,410
Capital assets acquired through accounts payable $ 9,021 $ 11,202
6
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS Saint Louis University
__________________________________________________________________________________________
(1) Summary of Significant Accounting Policies

(a) Organization
Saint Louis University (the University) was founded in 1818. The University is a coeducational institution
offering undergraduate and graduate programs in a variety of curricula. Professional degree programs include
medicine, law, business, social work, allied health, nursing, and advanced dentistry.
In addition to its higher education mission, the University devotes substantial resources, facilities, and
personnel to providing health care services in conjunction with the academic programs offered by the
University at the Medical Center. The University operates medical practices staffed by the faculty of the
University’s School of Medicine. The members of the faculty of the School of Medicine who provide medical
services are referred to as SLUCare.
(b) Presentation of Consolidated Financial Statements

The University’s consolidated financial statements have been prepared on the accrual basis of accounting in
conformity with U.S. generally accepted accounting principles (U.S. GAAP). The consolidated financial
statements include, after elimination of all significant intercompany transactions, the accounts of Saint Louis
University, SLUCare, Saint Louis University in Spain, and SLU Blocker (the holding company for Hotel
Ignacio and Robert May Hall).
(c) Tax Exempt Status

The University is generally exempt from Federal income tax pursuant to Section 501(c)(3) of the Internal
Revenue Code (the Code).
The Financial Accounting Standards Board (the FASB) issued guidance prescribing how an organization
should recognize, measure, present, and disclose uncertain tax positions in its consolidated financial
statements. The University adopted this guidance, which is included in Accounting Standards Codification
Topic 740 (ASC 740) Income Taxes. This guidance addresses the determination of how tax benefits claimed or
expected to be claimed on a tax return should be recorded in the consolidated financial statements. The
University must recognize the tax benefit from an uncertain tax position only if it is more likely than not that
the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the
position. The tax benefits recognized in the consolidated financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon
ultimate settlement. The University has no uncertain tax positions that result in material unrecognized tax
benefits as of June 30, 2017 and 2016.
(d) Measure of Operations

Net operating results (change in unrestricted net assets from operating activity) in the Consolidated Statements
of Activities reflect all transactions that change unrestricted net assets, except for activity associated with
consolidated endowment investments, gain or loss on swap agreements and certain other nonrecurring items. In
accordance with the University’s endowment spending policy, as described in Note 3, only the portion of total
investment return distributed under this policy to meet operating needs is included in operating revenue.
Operating investment income consists of dividends, interest, and realized/unrealized gains and losses on
unrestricted, nonendowed investments.
(e) Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.
________________________________________________________________________________________
7
(f) Revenue Recognition

The University recognized revenues from student tuition and fees within the fiscal year in which the academic
term is predominantly conducted. Deposits and deferred revenues include advance tuition deposits and
amounts billed to students for future years.
(g) Scholarship Allowances

Education revenues are reported net of scholarship allowances. A scholarship allowance represents the
difference between the stated charge for tuition and fees and the amount that is billed to the student and/or third
parties making payments on behalf of the student. Scholarship allowances were $151.2 million and
$139.4 million for the years ended June 30, 2017 and 2016, respectively.
(h) Contributions
Contributions received, including unconditional promises to give, are recognized as revenues in the period
received at their estimated fair values. For financial reporting purposes, the University distinguishes net assets
by classifying them as unrestricted, temporarily restricted, and permanently restricted. Contributions for which
donors have not stipulated restrictions, as well as contributions for which donors have stipulated restrictions
but which restrictions are met within the same reporting period, are reported as unrestricted. Contributions for
which donors have imposed restrictions (other than to be held in perpetuity) which limit the use of the donated
assets are reported as temporarily restricted if the restrictions are not met in the same reporting period. When
such donor-imposed restrictions are met in subsequent reporting periods, net assets are reclassified from
temporarily restricted to unrestricted and reported as net assets released from restrictions. Contributions of
assets which donors have stipulated must be maintained permanently, with only the income earned thereon
available for current use, are classified as permanently restricted. Changes in the allowance for doubtful
accounts are recorded as a reduction to contribution revenue.
Conditional promises to give are not recognized until the conditions on which they depend are substantially
met. Unconditional promises to give with payments due in future periods are reported as restricted support.
Gifts of land, buildings, and equipment are reported as unrestricted support unless explicit donor stipulations
specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify
how the assets are to be used and gifts of cash or other assets that must be used to acquire or construct
long-lived assets are reported as permanently restricted support. Absent explicit donor stipulation, the
University reports expirations of donor restrictions when the donated, acquired, or constructed long-lived
assets are placed in service.
(i) Auxiliary Enterprises Revenues

Auxiliary enterprises consist of revenues of the University’s residence halls, meal services, parking services,
and miscellaneous.
(j) Patient Care Revenues

SLUCare patient fee related charges and estimated adjustments are recorded at the time of service based on
current trends for payor mix, historical collection rates, and consideration for modifications in federal or
contractual reimbursement.
The health care industry is subject to numerous laws and regulations of federal, state, and local governments.
Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation.
Compliance with these laws and regulations, specifically those relating to the Medicare and Medicaid
programs, can be subject to review and interpretation, as well as regulatory actions unknown and unasserted at
this time. The federal government investigates allegations concerning possible violations of federal regulations
by health care providers. Such investigations could result in the imposition of fines, penalties, and the
potential repayment of previously billed and collected revenue from patient services. Management believes
that SLUCare is in substantial compliance with current laws and regulations.
8
In accordance with the mission of SLUCare, medical care is provided to individuals without insurance or other
means of paying for such care. Charity write-off is determined based on guidelines established by the
U.S. Department of Health and Human Services. Charges are recognized at the time of service and written off
as charity, if appropriate. During fiscal years 2017 and 2016, $1.4 million and $0.8 million, respectively, were
determined to be the cost of charity care. Costs are estimated using the ratio of patient care expenses to
charges.
The percentage of gross patient service revenue earned by payor for the years ended June 30, 2017 and 2016
were as follows:
Year ended June 30

2017 2016
Medicare 30 % 32 %
Medicaid 27 27
HMO 21 21
PPO 13 12
Self-pay 6 5
Other 3 3
Total 100 % 100 %
(k) Nonoperating Activities

Nonoperating activities consisted of the following:
Year ended June 30

2017 2016
Unrestricted net assets: (000’s omitted)
Investment return net of amounts designated for operations
in accordance with the University’s spending policy
Net return / (loss) on endowment funds $ 59,089 $ (52,432)
Net return / (loss) on designated funds 2,400 (7)
Investment return / (loss) on annuity/life income funds 784 (139)
Unrealized gains (losses) on interest rate swap agreements, net 16,767 (14,155)
Foreign currency translation adjustment 424 (14)
Reclassification to permanently restricted net assets (1,444) (1,588)
Other, net 719 (6,238)
Temporarily restricted net assets:
Investment return / (loss) 23,180 (19,800)
Other, net (116) (84)
Permanently restricted net assets:
Investment return 2,033 420
Reclassification from unrestricted net assets 1,444 1,588
Other, net 677 (1,464)
Total Nonoperating, net $ 113,112 $ (88,858)
(l) Cash and Cash Equivalents

Cash and cash equivalents include cash on hand and temporary investments purchased with an initial maturity
of three months or less. Cash and cash equivalents representing assets of endowment and similar funds are
included in investments in the Consolidated Statements of Financial Position. The carrying amount of cash and
cash equivalents approximates fair value due to the short maturity of these financial instruments.
9
(m) Accounts Receivable, Net

Accounts receivable are stated at estimated net realizable amounts. Accounts receivable were composed of the
following:
Allowance for
doubtful
Accounts accounts/ Accounts
receivable, contractual receivable,
gross allowances net
June 30, 2017
(000’s omitted)
Patient care $ 66,129 $ 35,540 $ 30,589
Pledges, discounted (see table below) 14,196 1,864 12,332
Government/private grants and contracts 10,906 390 10,516
Student accounts 25,040 1,928 23,112
Anticipated insurance recoveries 3,483 — 3,483
Other 11,409 4,119 7,290
Total $ 131,163 $ 43,841 $ 87,322
June 30, 2016

(000’s omitted)
Patient care $ 87,759 $ 38,762 $ 48,997
Pledges, discounted (see table below) 15,988 4,910 11,078
Government/private grants and contracts 10,421 115 10,306
Student accounts 20,127 1,941 18,186
Anticipated insurance recoveries 2,723 — 2,723
Other 11,283 3,681 7,602
Total $ 148,301 $ 49,409 $ 98,892
As of June 30, the maturities of pledges were distributed as follows:
2017 2016
Pledges scheduled to be collected in (000’s omitted)
Less than one year $ 5,137 $ 7,878
Between one year and five years 7,881 6,477
More than five years 3,000 3,600
Less: discount (rates range from 3.6% - 8.0%) (1,822) (1,967)
Pledges, discounted $ 14,196 $ 15,988
(n) Allowance for Doubtful Accounts – Patient Care

Patient care receivables are reduced by an allowance for doubtful accounts. The University evaluates the
collectability of accounts receivable through historical trend analysis by major payor source. The University
has not changed its charity care or uninsured discount policies during fiscal years 2017 or 2016.
(o) Investments
Investments in equity securities, investments in debt securities, unexpended bond proceeds, and funds held by
trustees, are reported at fair value. Absent a readily determinable fair value (RDFV), alternative investments
are valued using per share net asset value (NAV) provided by external investment managers as a practical
expedient in determining fair value. Because alternative investments may not be readily marketable, the
estimated value is subject to uncertainty and therefore may differ materially from the value that would have
been used had a ready market for the investments existed. Alternative investments include certain amounts
10
recorded as part of fixed maturity securities, equity securities, real estate investments/commodities, private
equity/venture capital, and hedge funds.
(p) Fair Value of Financial Instruments

As described in Note 4 and within other notes to the consolidated financial statements, the University accounts
for certain financial instruments at fair value only at origination (nonrecurring measurements) and certain
financial instruments as of the Consolidated Statements of Financial Position date (recurring measurements).
(q) Derivative Financial Instruments

The derivative instruments held by the University (as discussed in Notes 4 and 6) are recorded at fair value and
included within other accrued liabilities. Gains and losses from changes in derivative fair values are recognized
in the nonoperating investment return component of the Consolidated Statements of Activities.
(r) Notes Receivable

Notes receivable consisted of the following as of June 30:
2017 2016
(000’s omitted)
Federal government programs $ 17,292 $ 17,159
Institutional programs 6,073 6,899
Student notes receivable, net 23,365 24,058
Hotel Ignacio Investment Fund, LLC 9,527 9,527
Other 6 3
Notes receivable $ 32,898 $ 33,588
The University makes uncollateralized loans to students based on financial need. Student loans are funded
through Federal government loan programs or institutional resources. Such notes receivable include federally-
mandated repayment terms and interest rates ranging from 3% to 9%. Student loans represented 1.0% and
1.1% of total assets June 30, 2017 and 2016, respectively.
The University participates in the Perkins Federal Revolving Loan Program, Federal Primary Care Loan
program, and Federal Nursing Student Loan program. The availability of funds for loans under the programs is
dependent on reimbursements to the pool from repayments on outstanding loans. Funds advanced by the
federal government are ultimately refundable to the government and are classified as liabilities in the
Consolidated Statements of Financial Position. Funds advanced were $22.4 million and $24.3 million as of
June 30, 2017 and 2016, respectively. Outstanding loans cancelled under the program result in a reduction of
the funds available for loan and a decrease in the liability to the government. The following amounts were past
due under student loan programs as of June 30, 2017 and 2016:
1-60 Days 60-90 Days 90+ Days Total

June 30, past due past due past due past due
(000’s omitted)
2017 $ 7 7 2,035 $ 2,049
2016 $ 2 6 1,893 $ 1,901
As of June 30, 2017 and 2016, no reserves were recorded for the institutional program student loans. The
federal government guarantees Perkins loans. Therefore, no reserves are taken on any past due balances under
the program.
11
(s) Unexpended Bond Proceeds

Unexpended bond proceeds represent the amount of unspent revenue bond proceeds that remain available for
their specific purpose and are reported at fair value based upon market quotes. These amounts are maintained
in a trust and invested by the trustee in money market funds that invest in short-term U.S. Treasury securities.
Under the terms of the trust, proceeds are not released to the University until expenditures related to the
specific purpose of the bond indenture are incurred.
(t) Collections
Collections of art are capitalized at cost if purchased or at the fair market value at the date of gift if contributed.
Collections of art in the amount of $12.7 million were included in other assets within the accompanying
Consolidated Statements of Financial Position as of June 30, 2017 and 2016. These assets are not depreciated,
but are subject to impairment review.
(u) Other Accrued Liabilities

Other accrued liabilities were composed of the following:
June 30
2017 2016
(000’s omitted)
Fair value of derivative instruments (see Note 4) $ 33,796 $ 50,563
Actuarial estimated medical malpractice liability 27,450 25,131
Split-interest obligations (see Note 8) 10,449 10,626
Asset retirement obligations (see Note 5) 5,952 5,723
Other 1,962 2,962
Other accrued liabilities $ 79,609 $ 95,005
(v) U.S. Government Refundable Grants

U.S. Government refundable grants consist of funds advanced by the federal government on the condition that
the University administer various campus based student loan programs in compliance with federal regulations.
Under certain conditions, the funds must be returned to the federal government. Accordingly, they are
classified as liabilities in the Consolidated Statements of Financial Position.
(w) Foreign Currency Translation

The process of translating the University’s Spanish campus financial statements from euros to U.S. dollars
results in currency translation adjustments due to fluctuations in the exchange rate. The cumulative change in
unrestricted net assets related to foreign currency translation adjustments was $(4.4) million and $(4.8) million
as of June 30, 2017 and 2016, respectively.
(x) New Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which requires an
entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods
or services to customers. This ASU will replace most existing revenue recognition guidance in U.S. GAAP.
The University is required to apply the new revenue standard beginning July 1, 2018. The standard permits the
use of either the retrospective or cumulative-effect transition method. The University is evaluating the effect
that ASU 2014-09 will have on the consolidated financial statements and related disclosures and has not yet
determined the impact of the new standard on its current policies for revenue recognition.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under this guidance, an entity is
required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information
about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor, and sale
and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information
12
about leasing arrangements to enable a user of the financial statements to assess the amount, timing, and
uncertainty of cash flows from leases. This guidance is effective for annual reporting periods beginning after
December 15, 2018, and requires a modified retrospective adoption, with early adoption permitted. The
University is currently evaluating the impact on the consolidated financial statements and related disclosures
and has not yet determined the impact of the new standard.
In August 2016, the FASB issued ASU 2016-14, Presentation of Financial Statement of Not-for-Profit
Entities. The guidance changes how not-for-profit entities report net asset classes, expenses, investment return,
and liquidity in their financial statements. This ASU is effective for annual periods beginning after December
15, 2017. Retrospective application is required in the year of adoption. The University is currently evaluating
the impact on the consolidated financial statements and related disclosures and has not yet determined the
impact of the new standard.
(2) Third Party Reimbursed Health Programs

SLUCare
Medicare reimburses physician services according to the “Physicians’ Medicare Fee Schedule”, a national fee
schedule utilizing a Resource Based Relative Value System. Reimbursement under both the MO HealthNet
program and the Illinois Medicaid program is based on state-published fee schedules. Reimbursement under
the Medicaid Managed Care plans is based on plan-specific fee schedules for specialized services. Payment for
patient services covered by certain commercial insurance carriers, health maintenance organizations and
preferred provider organizations is based upon reimbursement agreements which include negotiated rates
and/or discounted fees for specific services.
Contractual agreements exist with third-party payors which provide for patient care reimbursement at rates
which differ from the established billing rates for such care. Revenues received by SLUCare are subject to
certain compliance requirements and audits by third-party payor groups which could result in retroactive
adjustments. Management is of the opinion that the ultimate disposition of any retroactive adjustments as a
result of such third-party audits would not have a material adverse effect on the University’s financial position
or changes in net assets.
(3) Investments
Investments were composed of the following:
June 30
2017 2016
(000’s omitted)
Fixed maturity securities 269,257 270,845
Equity securities 462,108 402,739
Real estate securities 92,069 129,229
Real assets – commodities 106,689 93,182
Private equity/venture capital 146,941 110,426
Hedge funds 126,120 119,713
Total investments $ 1,221,818 $ 1,141,542
The University designates only a portion of its cumulative investment return for support of current operations; the
remainder is reinvested to support operations of future years. The amount computed under the spending policy for
pooled long-term investments and certain investment income earned by investing cash in excess of daily requirements
are used to support current operations. These amounts are recorded within Education and Related Activities
operating revenue in the Consolidated Statement of Activities. Earnings on investments for which related purpose
restrictions are met in the year earned are recorded as unrestricted. Earnings on endowment net assets appropriated
for current year expenditure are also recorded as unrestricted.
13
Under the terms of certain limited partnership agreements, the University is obligated to periodically advance
additional funding for private equity/venture capital and real estate investments. The University had commitments of
approximately $185.5 million and $180.2 million for which capital calls had not been exercised as of June 30, 2017
and 2016, respectively. Of this total, $73.4 million and $76.9 million related to real asset/real estate investments and
$112.1 million and $103.3 million related to private equity/venture capital, respectively, as of June 30, 2017 and
2016.
Such commitments generally have fixed expiration dates or other termination clauses. The University maintains
sufficient liquidity in its investment portfolio to cover such calls.
The following schedules summarize the investment return/(loss) net of amounts designated for current operations, and
its classification in the Consolidated Statements of Activities excluding investments in irrevocable trusts that are
included in funds held by trustees:
Year ended June 30, 2017

Temporarily Permanently
(000’s omitted)
Dividends and interest $ 14,824 $ 31 $ 475 $ 15,330
Net realized and unrealized gains (losses) 117,745 23,149 1,558 142,452
Total return on investments 132,569 23,180 2,033 157,782
Cumulative investment return designated for current
operations (53,529) — — (53,529)
Investment return / (loss) net of amounts
designated for current operations $ 79,040 $ 23,180 $ 2,033 $ 104,253

(000’s omitted)
Dividends and interest $ 14,286 $ 30 $ 422 $ 14,738
Net realized and unrealized gains (losses) (27,368) (19,830) (2) (47,200)
Total return on investments (13,082) (19,800) 420 (32,462)
Cumulative investment return designated for current
operations (53,651) — — (53,651)
Investment return / (loss) net of amounts
designated for current operations $ (66,733) $ (19,800) $ 420 $ (86,113)
The total return/(loss) on investments includes custodial and management fees of $18.3 million and $14.6 million for
the years ended June 30, 2017 and 2016, respectively.
The University invests in various securities. These securities are exposed to various risks including interest rate,
market, and credit risks. Due to these risks it is reasonably possible that changes in value could occur in the near term.
Such changes could materially affect amounts reported in the Consolidated Statements of Financial Position.
14
(4) Fair Value Measurements

The FASB has established accounting principles related to “Fair Value Measurements and Disclosures” (ASC Topic
820). This defines fair value as the exchange price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date. The University follows this guidance in establishing a fair value
hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest
priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the
lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). Three levels of
inputs that may be used to measure fair value are as follows:
Level 1 includes observable inputs such as quoted prices in active markets that the University has the ability to
access at the measurement date.
Level 2 includes inputs such as quoted prices in markets that are not active or other inputs that are observable
or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
These financial instruments include split-interest agreements, pledges receivable, notes receivable, swap
agreements, notes and bonds payable.
Level 3 includes unobservable inputs in cases where there is little or no market data. This requires the
reporting entity to develop its own assumptions. Such financial instruments include estimated medical
malpractice liability, funds held by trustees, and patient care accounts receivable.
Management determines the University’s valuation policies by utilizing information provided by investment advisors,
third party pricing sources, and custodians. Management substantiates the reasonableness of third party pricing data
through review of methods, assumptions, recently executed transactions, existing contracts, economic conditions,
industry and market developments, and overall credit ratings.
The following discussion describes the valuation methodologies used for financial instruments measured at fair value.
Additional information regarding valuation methodologies is included within other notes to the consolidated financial
statements. The techniques utilized in estimating the fair values are affected by the assumptions used. Care should be
exercised in deriving conclusions about the University’s value or financial position based on the fair value
information of financial instruments presented below. There have been no changes in the valuation methodologies
used as of June 30, 2017 and 2016.
Fair market values of cash and cash equivalents are based on a share value price provided by the financial institution.
Fair values of fixed maturity securities and debt, excluding alternative investments, are based on prices provided by
the University’s investment managers and custodian bank. Both the investment managers and the custodian bank use
a variety of pricing sources to determine market valuations. These sources may include yields currently available on
comparable securities of issuers with similar credit ratings, dealer-supplied prices or by discounting future principal
and interest payments at prevailing interest rates. The fair value of holdings of mutual funds, common collective
trusts and commingled funds are determined by reference to the funds’ underlying assets, which are principally
marketable fixed income securities with quotes on national exchanges.
Fair values of equity securities, excluding alternative investments and funds held by trustees are based on quoted
market prices on national exchanges. To the extent that quoted market prices are not readily available, fair value may
be determined based on broker or dealer quotations or alternate pricing sources with reasonable levels of price
transparency.
15
Alternative investments include certain amounts recorded as part of fixed maturity securities, equity securities, private
equity/venture capital, hedge funds, and real estate investments/commodities. The strategy of such alternative
investments is as follows:
 Alternative investments in fixed maturity securities maintain a strategy to invest in a diversified portfolio of
marketable bonds, and other bond-like securities designed to add value and diversify risk.
 Alternative investments in equity securities maintain a strategy to invest in both domestic and international
marketable securities that offer the potential for investment return and diversify risk.
 Alternative investments in private equity/venture capital funds are longer-lived, and include an overall
investment strategy designed to enhance return and diversify risk through investing in limited partnership
interests and nonmarketable operating companies. Investment in such entities cannot be redeemed, yet the
University receives distributions through the liquidation of the underlying assets of the fund.
 Alternative investments in hedge funds include allocations to diversify investment strategies, which include
both marketable and nonmarketable securities, and include an overall investment strategy designed to enhance
return, diversify risk and dampen volatility by management of the hedge funds having the ability to shift
investments from value to growth strategies, from small to large capitalization stocks, and from a net long
position to a net short position.
 Alternative investments in real estate include an overall investment strategy designed to enhance return and to
diversify risk within the investment portfolio by investing in the form of limited partnerships in operating
companies that invest in U.S. real estate. This category also includes investments in commodities, which
provide a hedge against inflation.
 Alternative investments in real assets – commodities have an overall investment strategy designed to enhance
return and diversify risk within the investment portfolio by investing in liquid instruments of a wide array of
commodity investments, which provide a hedge against inflation.
Absent a RDFV, alternative investments are valued using NAVs provided by external investment managers as a
practical expedient in determining fair value. NAVs provided by external investment managers include estimates,
appraisals, assumptions, and methods that are reviewed by management. It is possible that the redemption rights may
be restricted by the funds in the future in accordance with the underlying fund agreements. Changes in market
conditions and the economic environment may impact the NAV of the funds and, consequently, the fair value of the
University’s interests in the funds.
Unexpended bond proceeds are invested in various securities based on expected risk, returns and maturities that
mirror the anticipated timing of construction project payment needs. Fair values of unexpended bond proceeds
securities are based on prices provided by the trustee bank. Unexpended bond proceeds include cash equivalents and
fixed income securities where their fair values are based on observable market quotation prices. The trustee bank uses
a variety of pricing sources to determine market valuations of fixed maturity securities. The specific pricing services
or indexes for each sector of the market are based upon the provider’s expertise. The fixed maturity securities are
highly liquid, allowing the portfolio to be priced through pricing services.
The University’s swap agreements are valued using observable market data, swap rates, and basis rates. These inputs
are placed into proprietary models to calculate the Mark-to-Market value of the interest rate swaps. The
Mark-to-Market pricing is validated by management of the University.
16
The following tables summarize the University’s fair value hierarchy, investments valued using NAV, and
redemption/ liquidity information:
Recurring financial assets: June 30, 2017 June 30, 2016 Redemption/ Days’
Level 1 Assets: (000’s omitted) liquidation notice
Investments:
Cash and cash equivalents 18,634 15,408
Fixed maturity securities 269,257 270,845
Domestic equity 230,879 201,247
International equity 96,796 200,819
Real asset commodities equity 18,633 47,629
Total Level 1 Investments 634,199 735,948
Investments valued using NAV (1):
Alternative investments-equity securities 134,433 (2) 673 (2) Monthly/Illiquid
Alternative investments-real estate commodities 34,637 — Monthly
Alternative investments-private equity/venture capital 146,941 110,426 Illiquid
Alternative investments-hedge funds 126,120 119,713 Daily to > 1-year 1 to 90
Alternative investments-real asset commodities 53,419 45,553 Illiquid
Alternative investments-real estate investments 92,069 (3) 129,229 (3) Quarterly/Illiquid 90
Total NAV Investments 587,619 405,594
Total investments 1,221,818 1,141,542
Unexpended bond proceeds (Level 1) 12,494 9,252
Funds held by trustees (Level 3) 59,117 54,440 Illiquid
Total recurring assets $ 1,374,280 $ 1,239,621
Recurring financial liabilities (Level 2):
Swap agreements $ 33,796 $ 50,563
NOTES
(1) Certain investments that are measured at fair value using NAV as a practical expedient have not been categorized in the fair value hierarchy.
(2) Alternative investments-equity securities include $0.05 million and $0.67 million which are illiquid as of June 30, 2017 and 2016, respectively.
(3) Alternative investments-real estate include $61.4 million and $73.3 million which are illiquid as of June 30, 2017 and 2016, respectively.
Certain alternative investments include gates or other redemption restrictions. Such restrictions were immaterial as of
June 30, 2017 and 2016. Certain private equity/venture capital and real estate investments cannot be redeemed with
the investee, but the University receives distributions through the liquidation of underlying assets.
The following table rolls forward the balance of Funds Held by Trustee measured at fair value on a recurring basis:
Level 3 assets
Financial assets: June 30, 2017 June 30, 2016
Beginning balance $ 54,440 $ 54,862
Investment income including realized gains 638 255
Unrealized gains / (losses) 2,190 (2,020)
Purchases 2,541 1,819
Sales (692) (476)
Ending balance $ 59,117 $ 54,440
17
(5) Land, Buildings and Equipment, net

Physical properties consisted of the following:
June 30
2017 2016
(000’s omitted) (000’s omitted)
Land $ 63,877 $ 67,721
Buildings and building improvements 875,828 822,840
Equipment 137,666 138,879
Construction in progress 92,917 67,893
Land, buildings, and equipment 1,170,288 1,097,333
Less accumulated depreciation (486,840) (464,385)
Land, buildings, and equipment, net $ 683,448 $ 632,948
Buildings and equipment are stated at cost, less accumulated depreciation. Land is stated at cost at the date of
acquisition or estimated fair value at date of contribution. Maintenance, repairs, and minor renewals are expensed as
incurred. Depreciation is calculated on the straight-line basis. Depreciable lives are estimated as 40-50 years for
buildings, 10-35 years for building improvements, and 3-15 years for equipment.
Construction in progress consists of construction expenditures for physical properties that have not yet been placed in
service. The University has entered into construction contracts with unrelated parties in the amount of $81.8 million
(including change orders), for the construction or rehabilitation of various real properties. At June 30, 2017,
$11.2 million of such contract commitments had not yet been incurred.
Asset Retirement Obligation

U.S. GAAP defines a conditional asset retirement obligation as a legal obligation to perform an asset retirement
activity in which the timing and (or) method of settlement are conditional on a future event that may or may not be
within the control of the entity. Uncertainty with respect to the timing and/or method of settlement of the asset
retirement obligation, does not defer recognition of a liability. The obligation to perform the asset retirement activity
is unconditional, and accordingly, a liability should be recognized. These rules also provide guidance with respect to
the criteria to be used to determine whether sufficient information exists to reasonably estimate the fair value of an
asset retirement obligation. Based on these rules, management of the University determined that sufficient
information was available to reasonably estimate the fair value of known retirement obligations. Therefore, the
University recognized interest and depreciation expenses of $0.3 million in operating expenses within the
Consolidated Statements of Activities for years ended June 30, 2017 and 2016. Asset retirement costs of $0.5 and
$0.6 million, net of accumulated depreciation, were included in land, buildings and equipment, net as of June 30,
2017 and 2016, respectively. Conditional asset retirement obligations of $6.0 million and $5.7 million were included
within other accrued liabilities in the Consolidated Statements of Financial Position as of June 30, 2017 and 2016,
respectively.
18
(6) Debt Agreements

Outstanding balances of notes and bonds payable are summarized below:
June 30
Description 2017 2016
Twenty year Health and Educational Facilities Revenue Bonds – Series 1998.
Interest rates range from 5 to 5.5%. $ — $ 4,815
Twenty-five year Health and Educational Facilities Variable Rate Demand

Revenue Bonds – Series A and B 1999. Interest rate is variable
(.93% at June 30, 2017), with a maximum of 12%. 50,600 51,080
Thirty year Health and Educational Facilities Variable Rate Demand Revenue
Bonds – Series 2002. Interest rate is variable (.89% at June 30, 2017),
with a maximum of 12%. 6,150 6,780
Thirteen year Health and Educational Facilities Variable Rate Demand Revenue
Bonds – Series 2003A. Interest rate is variable, with a maximum of 12%. — 535
Twenty-seven year Health and Educational Facilities Variable Rate Demand

Revenue Bonds – Series 2008 B1 and B2. Interest rates are variable
(.89 to .96% at June 30, 2017) with a maximum of 12%. 83,150 157,215
NTCIC – Hotel Ignacio Project, LLC, note payable

Maturing 12/15/2043 – Interest rate 2.2%. 7,000 7,000
St. Louis New Markets Tax Credit Fund – XVI, LLC, note
payable Maturing 12/15/2043 – Interest rate 2.2%. 5,000 5,000
Twenty-seven year Health and Educational Facilities Revenue Bonds – Series 2015A.
Interest rates range from 4 to 5%. 57,435 57,435
Thirty year Taxable Health and Educational Facilities Revenue Bonds – Series 2015B.
Interest rate 4.756%. 40,360 40,360
Nineteen year Health and Education Facilities Revenue Bonds - Series 2016 A1 and
A2. Interest rates are variable (1.32% at June 30, 2017) with a maximum of 12%. 71,930 —
Thirty year Health and Education Facilities Revenue Bonds - Series 2017 A.
Interest rates range from 3.75% to 5.0%. 76,455 —
SLH Vista, Inc., unsecured promissory note

Interest free, maturing 08/31/2025 10,000 10,000
Notes and bonds payable, par 408,080 340,220
Net unamortized original bond issue premium/discount 5,099 1,453
Unamortized debt issuance cost (2,127) (1,459)
$ 411,052 $ 340,214
19
The University’s Health and Educational Facilities Series 1998, Series 1999, Series 2002, Series 2003A, Series 2008
B1, and B2, and Series 2015A and B bonds are parity obligations that are not secured by a pledge or security interest
in any specific property of the University other than the security interest in any funds deposited and held by either the
applicable bond trustee or the Master Trustee under the University’s Master Trust Indenture. The University is
required to comply with certain restrictive covenants under these bond agreements. The University is in compliance
with these covenants as of June 30, 2017. Certain bonds are subject to early redemptions at the option of the
University.
Additions to debt during the year included the issuance of $71.9 million of Health and Educational Facilities Revenue
Bonds, Series 2016, and $76.5 million in tax-exempt, fixed-rate bonds, Series 2017A. The proceeds of the Series
2016 bonds were used to refinance and refund Health and Educational Facilities Variable Rate Demand Revenue
Bonds, Series 2008A. The proceeds of the 2017A bonds were used to finance a new residence hall, acquire an
existing building on the University’s medical campus and for other various capital projects.
Note and bond principal payments amount to $9.5 million, $13.1 million, $10.1 million, $10.5 million and $13.9
million for fiscal years 2018 through 2022, respectively. Certain debt obligations require the maintenance of bond and
interest sinking funds. Interest paid was $13.6 million and $10.4 million during fiscal years 2017 and 2016,
respectively.
The University has entered into various interest rate swap agreements. These swap agreements represent the
University’s only derivative instruments and are accounted for as cash flow hedges. As a cash flow hedge, the gain or
loss on the swap agreements are recognized within the Consolidated Statements of Activities as part of nonoperating
investment return. Gains in the amount of $16.8 million and losses in the amount of $(14.2) million were recognized
related to the swap agreements for the years ended June 30, 2017 and 2016, respectively. Additionally, the impact
within operating activities of the Consolidated Statements of Cash Flows was ($6.0) and ($6.8) million for the years
ended June 30, 2017 and 2016, respectively.
The University holds these derivative instruments for the fixed interest rate certainty they provide. Therefore, the
University entered into interest rate swap agreements to fix the rate of interest on the Health and Education Facilities
Variable Rate Demand Revenue Bonds as follows, as of June 30, 2017:
Weighted
Notional Maturity average
Revenue bonds amount date interest rate (%)
($ in millions)
Series 1999 $ 50.6 2024 3.80
Series 2002 6.2 2026 3.10
Series 2008 B1 26.2 2026 3.04
Series 2008 B2 56.6 2035 3.61
Series 2016 A1 7.0 2018 3.06
Series 2016 A2 64.3 2035 3.25
The University has a standby bond purchase agreement with a maximum principal amount of $6.2 million to provide
liquidity for the outstanding balance related to the Series 2002 Health and Educational Facilities Variable Rate
Demand Revenue Bonds. This standby bond purchase agreement expires on October 28, 2019. In the event the
remarketing agent is unable to remarket the bonds, the bank would draw on the standby bond purchase agreement to
purchase the bonds. Any liquidity advances would require repayment over 90 days. The University has irrevocable
letters of credit with a maximum principal amount of $133.8 million to provide liquidity for the outstanding balances
related to the Series 1999 and 2008B Health and Educational Facilities Variable Rate Demand Revenue Bonds. The
letter of credit for the Series 1999 has an expiration date of June 2, 2022. The letters of credit for Series 2008B-1 and
2008B-2 have expiration dates of October 28, 2020 and September 27, 2019, respectively. Series 2008A was
refunded by Series 2016 on October 21, 2016.
The University has a line of credit in the original amount of $25 million with Wells Fargo Bank, N.A., at a base rate
of daily one month LIBOR plus 0.40%. The University had no outstanding borrowings under the line of credit as of
20
June 30, 2017. Additionally, the University had a line of credit in the original amount of $25 million with U.S Bank,
N.A., at a base rate of daily one month LIBOR plus 0.40%. The University has established letters of credit in the
amount of $0.9 million which reduce the amount available to borrow on the US Bank, N.A. line of credit to
$24.1 million as of June 30, 2017.
(7) Lease Obligations

The University leases certain equipment and conducts certain operations in leased facilities. Terms of these operating
leases, including renewals, maintenance costs and purchase options, vary by lease. Total rental expense charged to
operations was approximately $6.8 million and $6.4 million for the fiscal years ended June 30, 2017 and 2016,
respectively. As of June 30, 2017, future minimum annual lease payments under noncancelable operating leases are
$5.3 million, $5.2 million, $4.8 million, $1.7 million, and $1.1 million for fiscal years 2018 through 2022,
respectively.
(8) Split-Interest Agreements

The University has certain split-interest agreements with donors which consist primarily of charitable gift annuities,
charitable remainder annuity trusts, and charitable remainder unitrusts for which the University serves as trustee.
Assets are invested and payments are made to donors and/or other beneficiaries in accordance with respective
agreements. Contribution revenues for charitable gift annuities and charitable remainder trusts are recognized after
recording liabilities for the present value of the estimated future payments to be made to the respective donors and/or
other beneficiaries. The University reported split-interest obligations of $10.4 million and $10.6 million as of June 30,
2017 and 2016, respectively. These amounts are included within other accrued liabilities in the Consolidated
Statements of Financial Position. The fair value of split-interest agreement related assets total $11.5 million and
$11.3 million as of June 30, 2017 and 2016, respectively. The discount rate used to value split-interest agreements
ranged from 3.6% to 7.0% for June 30, 2017 and 2016.
(9) Functional Expenses

The University’s classifications of expenses in the Consolidated Statements of Activities are combined by functional
category as follows:
Year ended June 30

2017 2016
Patient care $ 332,200 $ 321,594
Instruction 201,999 201,179
Research 37,214 34,567
Public service 9,700 11,375
Academic support 55,377 57,352
Student services 26,929 27,065
Institutional support 103,637 92,983
Total operating expenses $ 808,926 $ 788,479
The University’s primary education and related activities programs are instruction, research, and public service.
Academic support, student services, and auxiliary services are considered integral to the delivery of these programs.
Certain overhead and other costs have been allocated among the functional expense categories benefited. Fundraising
costs are not material to the University’s total program costs. Costs related to the operation, maintenance, and
depreciation of the physical plant are allocated to operating programs and supporting activities based upon periodic
facility usage surveys. Interest expense on external debt is recorded as institutional support.
21
(10) Restricted Net Assets

The University’s temporarily restricted net assets are available for the following purposes:
June 30
2017 2016
Buildings and equipment $ 1,369 $ 1,213
Annuity/life income trust agreements 763 620
Educational activity purposes 137,508 114,749
Temporarily restricted net assets $ 139,640 $ 116,582
The University’s permanently restricted net assets are restricted to:

June 30
2017 2016
Investment in perpetuity, the income from which is generally (000’s omitted) (000’s omitted)
expendable to support educational activity purposes $ 294,835 $ 282,988
Annuity/life income trust agreements 5,879 6,557
Student loans 8,357 8,217
Permanently restricted net assets $ 309,071 $ 297,762
(11) Endowment Funds

(a) Interpretation of Relevant Law
The University follows accounting rules outlined in “Endowments of Uniform Prudent Management of
Institutional Funds Act, and Enhanced Disclosures for All Endowment Funds” which provides guidance on the
net asset classification of donor restricted endowment funds for not-for-profit organizations. The State of
Missouri enacted the Uniform Prudent Management of Institutional Funds Act (UPMIFA) on August 28, 2009.
The University’s governing board has interpreted the Uniform Prudent Management of Institutional Funds Act
(UPMIFA) enacted in the State of Missouri as requiring the preservation of the fair value of the original gift as
of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a
result of this interpretation, the University classifies as permanently restricted net assets (a) the original value
of the gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent
endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the
applicable donor gift instrument at the time the accumulation is added to the fund.
The remaining portion of the donor-restricted endowment fund that is not classified as permanently restricted
net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure
by the University in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance
with UPMIFA, the University considers the following factors in making a determination to appropriate or
accumulate donor-restricted endowment funds:
1. The duration and preservation of the fund

2. The purposes of the University and the donor-restricted endowment fund
3. General economic conditions
4. The possible effect of inflation and deflation
5. The expected total return from income and the appreciation of investments
6. Other resources of the University
7. The investment policies of the University
(b) Endowment Spending Policy

The University’s spending policy annually allocates the amount of the total returns which can be spent and
reinvested for future earnings. The spending rate, which is annually approved by the Board of Trustees, is
5.0% of the average market value per unit for a twelve quarter period for the Pooled Endowment for June 30,
2017 and 2016.
The Annual Spending Rate per Unit (ASRU) is calculated as of each December 31 by multiplying the current
spending rate by the average market value per unit for the previous twelve quarters. The ASRU is then
22
multiplied by the number of units owned by each endowment fund to determine the spending budget for each
fund for the following fiscal year. The spending is credited to the appropriate operating fund at the beginning
of the next fiscal year.
The difference between the actual total return and return designated for current operations is classified as
nonoperating income or expense in the Consolidated Statements of Activities.
(c) Endowment Investment Policy

The University has adopted investment and spending policies for endowment assets that will preserve and
enhance the real (inflation-adjusted) purchasing power of the pooled endowment while providing an increasing
stream of real funding for the annual University budget in the future. Endowment assets include those assets of
donor-restricted funds that the University must hold in perpetuity or for a donor-restricted period(s) as well as
quasi endowment funds. Under this policy, the University’s return objectives and risk parameters attempt to
achieve the highest long-term total investment return on investment assets that is compatible with the
University’s risk tolerance and time horizons consistent with prudent investment practices. The primary
investment objective is to provide a net annual return equal to the spending rate, plus the rate of inflation, plus
1% – 2%. To achieve its investment objective, the Pooled Endowment fund is allocated among investments
that are further characterized as “Equity”, “Alternative”, and “Fixed Income”. The primary objective of the
allocation between these three major asset classes is to provide a strategic mix that produces the highest risk
adjusted return through a responsible and disciplined investment approach.
(d) Endowment Funds with Deficiencies and Other Matters

From time to time, the fair value of the assets associated with individual donor-restricted endowment funds
may fall below the level that is required to retain as a fund of perpetual duration. Deficiencies of this nature
that are reported in unrestricted net assets were $(1.1) million and $(3.8) million as of June 30, 2017 and 2016,
respectively. These deficiencies resulted from unfavorable market fluctuations. The following table presents
endowment net asset composition by fund type:
(000’s omitted)
June 30, 2017
Donor-restricted endowment funds $ (1,097) $ 128,035 $ 294,106 $ 421,044
Quasi/Board-designated
endowment funds 728,546 — — 728,546
Total funds $ 727,449 $ 128,035 $ 294,106 $ 1,149,590
June 30, 2016

Donor-restricted endowment funds $ (3,816) $ 105,005 $ 282,259 $ 383,448
Quasi/Board-designated
endowment funds 669,587 — — 669,587
Total funds $ 665,771 $ 105,005 $ 282,259 $ 1,053,035
Endowment income, including endowment investment return, appropriated for expenditure within the same
fiscal year in accordance with the University’s annual spending rate are reported within endowment
unrestricted net assets. The following table rolls forward the balance of endowment net assets:
23
(000's omitted)
Endowment net assets, June 30, 2015 $ 692,205 $ 124,746 $ 276,394 $ 1,093,345
Investment return:
Investment income 9,849 5 205 10,059
Investment / other income - non pooled 1,904 — — 1,904
Net realized / unrealized gains / (losses) (12,851) (19,759) (1,127) (33,737)
Contributions — 12 5,199 5,211
Endowment assets appropriated
for expenditure (51,335) — — (51,335)
Reclassification based on donor intent — 1 1,588 1,589
Transfers to create board-
designated funds 25,999 — — 25,999
Investment return:
Investment income 11,571 6 241 11,818
Investment / other income - non pooled 2,056 — — 2,056
Net realized / unrealized gains / (losses) 99,839 22,975 1,936 124,750
Contributions — 49 8,228 8,277
Endowment assets appropriated
for expenditure (54,378) — — (54,378)
Reclassification based on donor intent — — 1,442 1,442
Gain (loss) on other assets 30 — — 30
Transfers to create board-
designated funds 2,560 — — 2,560
(12) Insurance Programs

The University has insurance coverage for medical malpractice and health insurance claims which is subject to certain
aggregate, per claim, and self-insurance retention limits. The University participates with other universities in
self-insurance risk pools which provide some of the University’s workers’ compensation, general liability, and
property coverage. Whenever the pools’ actual losses exceed estimates, the University can be required to contribute
additional funds. Management believes that any such additional contributions would not have a material effect on the
University’s financial position or changes in net assets.
(13) Retirement Benefits

Retirement benefits for University employees are provided through the Teachers Insurance and Annuity Association
(TIAA) and Fidelity Investments. Contributions are made to provide individually owned retirement contracts and
accounts for participating employees. Employees are eligible for the University’s retirement plan after one year of
continuous service. The University provides a two to one matching contribution up to a maximum of 10% as the
University’s contribution. Contributions made by the University are vested immediately. The University’s share of
the cost of these benefits was $29.5 million and $28.5 million for the fiscal years ended June 30, 2017 and 2016,
respectively.
(14) Governmental Grants and Contracts

The University has recovered indirect costs under certain grants and contracts with federal agencies for both the 2017
and 2016 fiscal years. These recoveries are reported as unrestricted revenue. Indirect cost rates vary according to the
terms of the grant award or the contract. Most rates are based on modified total direct costs. Certain research grants
and contracts allow indirect costs based on an indirect cost research rate that is negotiated with the Department of
Health and Human Services.
24
(15) Hospital Affiliations

The University’s academic affiliation agreement with Tenet Healthcare (Tenet) ended on August 31, 2015. As of
September 1, 2015, the University entered into a fifty-year Academic Affiliation and Services Agreement with SSM
Health Care Corporation, SSM Health Care St. Louis, SSM Cardinal Glennon Children’s Hospital, and SSM-SLUH,
Inc.(SSM). Under this agreement, the University receives funding for: the supervision of residents,
education/academic services, professional clinical services, administrative and other purchased services, faculty
recruitment and research support. The University and SSM also have master lease agreements through which either
entity may lease space to or from the other. In accordance with a Member’s Agreement of SSM Health Care St.
Louis, the University repurchased Saint Louis University Hospital from Tenet and contributed the Hospital to SSM-
SLUH, Inc., a wholly owned subsidiary of SSM Health Care St. Louis, in exchange for a 15% financial interest and
governance rights in SSM Health Care St. Louis. The University does not exercise significant influence over
operating and financial policies, nor does the University have a controlling financial interest in SSM Health Care St.
Louis.
Revenues associated with the above described hospital affiliation transactions for the fiscal years ended June 30, 2017
and 2016 are $170.7 million and $140.3 million, respectively. Expenses associated with the above described hospital
affiliation transactions for the fiscal years ended June 30, 2017 and 2016 are $6.7 million and $6.4 million,
respectively. Hospital affiliation revenues and expenses are included as components of patient care and supplies,
repairs, utilities, & other expenses within the Consolidated Statements of Activities. Amounts due from SSM as of
June 30, 2017 and 2016, were $10.2 million and $21.0 million, respectively, and are included as components of
accounts receivable, net within the Consolidated Statements of Financial Position.
(16) Legal Matters – Contingencies, Commitments and Other

There are various lawsuits and legal proceedings against the University which are in varying states of review and may
proceed for protracted periods of time. Management is of the opinion that the ultimate disposition of such litigation
will not have a material adverse effect on the University’s financial position or changes in net assets.
(17) Subsequent Events

In connection with the preparation of the consolidated financial statements, the University evaluated subsequent
events, and noted no additional items to disclose through October 23, 2017, which was the date the consolidated
financial statements were issued.
25
Uniform Guidance Single Audit Report
(With Independent Auditors’ Reports Thereon)
Uniform Guidance Single Audit Report
Table of Contents
Page(s)
Independent Auditors’ Report on Internal Control over Financial Reporting and on Compliance
and Other Matters Based on an Audit of Financial Statements Performed in Accordance
With Government Auditing Standards 1–2
Independent Auditors’ Report on Compliance for Each Major Federal Program; Report on
Internal Control over Compliance; and Report on Schedule of Expenditures of Federal
Awards Required by the Uniform Guidance 3–5
Schedule of Expenditures of Federal Awards 6–23
Notes to Schedule of Expenditures of Federal Awards 24–25
Schedule of Findings and Questioned Costs 26–32
Saint Louis University’s audited consolidated financial statements, as of and for the year ended
June 30, 2017, are separately attached hereto.
KPMG LLP
Suite 900
10 South Broadway
St. Louis, MO 63102-1761
Independent Auditors’ Report on Internal Control over Financial Reporting and on Compliance and
Other Matters Based on an Audit of Financial Statements Performed in Accordance With
Government Auditing Standards
The Board of Trustees

Saint Louis University:
We have audited, in accordance with the auditing standards generally accepted in the United States of America
and the standards applicable to financial audits contained in Government Auditing Standards, issued by the
Comptroller General of the United States, the consolidated financial statements of Saint Louis University, which
comprise the consolidated statement of financial position as of June 30, 2017, and the related consolidated
statements of activities and cash flows for the year then ended, and the related notes to the consolidated
financial statements, and have issued our report thereon dated October 23, 2017.
Internal Control over Financial Reporting

In planning and performing our audit of the (consolidated) financial statements, we considered Saint Louis
University’s internal control over financial reporting (internal control) to determine the audit procedures that are
appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial
statements, but not for the purpose of expressing an opinion on the effectiveness of Saint Louis University’s
internal control. Accordingly, we do not express an opinion on the effectiveness of Saint Louis University’s
internal control.
A deficiency in internal control exists when the design or operation of a control does not allow management or
employees, in the normal course of performing their assigned functions, to prevent, or detect and correct,
misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal
control, such that there is a reasonable possibility that a material misstatement of the entity’s financial
statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a
deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet
important enough to merit attention by those charged with governance.
Our consideration of internal control was for the limited purpose described in the first paragraph of this section
and was not designed to identify all deficiencies in internal control that might be material weaknesses or
significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal
control that we consider to be material weaknesses. However, material weaknesses may exist that have not
been identified.
Compliance and Other Matters

As part of obtaining reasonable assurance about whether Saint Louis University’s consolidated financial
statements are free from material misstatement, we performed tests of its compliance with certain provisions of
laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material
effect on the determination of financial statement amounts. However, providing an opinion on compliance with
those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The
results of our tests disclosed no instances of noncompliance or other matters that are required to be reported
under Government Auditing Standards.
KPMG LLP is a Delaware limited liability partnership and the U.S. member
firm of the KPMG network of independent member firms affiliated with
KPMG International Cooperative (“KPMG International”), a Swiss entity.
Purpose of this Report
The purpose of this report is solely to describe the scope of our testing of internal control and compliance and
the results of that testing, and not to provide an opinion on the effectiveness of the Saint Louis University’s
internal control or on compliance. This report is an integral part of an audit performed in accordance with
Government Auditing Standards in considering the Saint Louis University’s internal control and compliance.
Accordingly, this communication is not suitable for any other purpose.
St Louis, Missouri
October 23, 2017
2
KPMG LLP
Suite 900
10 South Broadway
St. Louis, MO 63102-1761
Independent Auditors’ Report on Compliance for Each Major Federal Program; Report on Internal
Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the
Uniform Guidance
The Board of Trustees

Saint Louis University:
Report on Compliance for Each Major Federal Program

We have audited Saint Louis University’s compliance with the types of compliance requirements described in
the OMB Compliance Supplement that could have a direct and material effect on Saint Louis University’s major
federal programs for the year ended June 30, 2017. Saint Louis University’s major federal programs are
identified in the summary of auditors’ results section of the accompanying schedule of findings and questioned
costs.
Management’s Responsibility
Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of
its federal awards applicable to its federal programs.
Auditors’ Responsibility
Our responsibility is to express an opinion on compliance for each of Saint Louis University’s major federal
programs based on our audit of the types of compliance requirements referred to above. We conducted our
audit of compliance in accordance with auditing standards generally accepted in the United States of America;
the standards applicable to financial audits contained in Government Auditing Standards, issued by the
Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal
Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for
Federal Awards (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and
perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance
requirements referred to above that could have a direct and material effect on a major federal program
occurred. An audit includes examining, on a test basis, evidence about Saint Louis University’s compliance with
those requirements and performing such other procedures as we considered necessary in the circumstances.
We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal
program. However, our audit does not provide a legal determination of Saint Louis University’s compliance.
Opinion on Each Major Federal Program

In our opinion, Saint Louis University complied, in all material respects, with the types of compliance
requirements referred to above that could have a direct and material effect on each of its major federal
programs for the year ended June 30, 2017.
Other Matters
The results of our auditing procedures disclosed an instance of noncompliance, which are required to be
reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of
findings and questioned costs as item 2017-002. Our opinion on each major federal program is not modified
with respect to this matter.
KPMG LLP is a Delaware limited liability partnership and the U.S. member
firm of the KPMG network of independent member firms affiliated with
KPMG International Cooperative (“KPMG International”), a Swiss entity.
The University’s response to the noncompliance finding identified in our audit is described in the accompanying
schedule of findings and questioned costs. The University’s response was not subjected to the auditing
procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.
Report on Internal Control over Compliance

Management of Saint Louis University is responsible for establishing and maintaining effective internal control
over compliance with the types of compliance requirements referred to above. In planning and performing our
audit of compliance, we considered Saint Louis University’s internal control over compliance with the types of
requirements that could have a direct and material effect on each major federal program to determine the
auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on
compliance for each major federal program and to test and report on internal control over compliance in
accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of
internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Saint Louis
University’s internal control over compliance.
A deficiency in internal control over compliance exists when the design or operation of a control over
compliance does not allow management or employees, in the normal course of performing their assigned
functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal
program on a timely basis. A material weakness in internal control over compliance is a deficiency, or
combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that
material noncompliance with a type of compliance requirement of a federal program will not be prevented, or
detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a
deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance
requirement of a federal program that is less severe than a material weakness in internal control over
compliance, yet important enough to merit attention by those charged with governance.
Our consideration of internal control over compliance was for the limited purpose described in the first
paragraph of this section and was not designed to identify all deficiencies in internal control over compliance
that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant
deficiencies may exist that have not been identified. We did not identify any deficiencies in internal control over
compliance that we consider to be material weaknesses. However, we identified certain deficiencies in internal
control over compliance, as described in the accompanying scheduled of findings and questioned costs as
items 2017-001 and 2017-002 that we consider to be significant deficiencies.
Saint Louis University’s responses to the internal control over compliance findings identified in our audit are
described in the accompanying schedule of findings and questioned costs. Saint Louis University’s responses
were not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express
no opinion on the responses.
The purpose of this report on internal control over compliance is solely to describe the scope of our testing of
internal control over compliance and the results of that testing based on the requirements of the Uniform
Guidance. Accordingly, this report is not suitable for any other purpose.
4
Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance
We have audited the consolidated financial statements of Saint Louis University as of and for the year ended
June 30, 2017, and have issued our report thereon dated October 23, 2017, which contained an unmodified
opinion on the consolidated financial statements. Our audit was conducted for the purpose of forming an
opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of
federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not
a required part of the consolidated financial statements. Such information is the responsibility of management
and was derived from and relates directly to the underlying accounting and other records used to prepare the
consolidated financial statements. The information has been subjected to the auditing procedures applied in the
audit of the consolidated financial statements and certain additional procedures, including comparing and
reconciling such information directly to the underlying accounting and other records used to prepare the
consolidated financial statements or to the consolidated financial statements themselves, and other additional
procedures in accordance with auditing standards generally accepted in the United States of America. In our
opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the
consolidated financial statements as a whole.
St. Louis, Missouri

February 19, 2018
5
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2017
Awards Subtotal
Passed By Cluster/
Grant/Program Title Payment CDFA FY2017 Through to Subtotal Subtotal Other
Pass-Through Entity Source Number Award Number Expenditures Subrecipients By Program By Agency Programs
Student Financial Assistance Cluster

84 Department of Education
FSEOG 2016-2017 Direct 84.007 P007A162375 1,039,579
FWS 2016-2017 Direct 84.033 P033A162375 899,018
Federal Perkins Loan Program Direct 84.038 P038A022375 15,935,404
Pell 2016-2017 Direct 84.063 397017 5,979,768

PELL Program 2015-2016 Direct 84.063 P063P151755 -2,667
Total for CFDA Number 84.063 5,977,101
Direct Loan Program 2015-2016 Direct 84.268 P268K161755 291,483

Direct Loan Program 2016-2017 Direct 84.268 P268K171755 109,680,543
Direct Loan Program 2017-2018 Direct 84.268 P268K171755 6,670,621
Total for Department of Education 140,493,749
93 Department of Health and Human Services
Nurse Faculty Loan Program Direct 93.264 E01HP12987-01-00 283,622
Loans for Disadvantaged Students Direct 93.342 7056108-06 333,503

Primary Care Loans Direct 93.342 7056101H-00 2,469,325
ARRA-Nurse ARRA Award Direct 93.364 E0AHP15402-01-00 28,460

Nursing Student Loan Program Direct 93.364 7056831-08 947,481
Total for CFDA Number 93.364 975,941
Total for Department of Health and Human Services 4,062,391
Total for Student Financial Assistance Cluster 144,556,140
6 (Continued)
Awards Subtotal
Passed By Cluster/
Research and Development Cluster

10 United States Department of Agriculture
Investigating functions of transcription factor genes in plant seed development Direct 10.001 58-5070-6-023 3,508
Subtotal for United States Department of Agriculture -Direct 3,508
Curators of the University of Missouri Pass-Through 10.253 00054141-1 13,946
Board of Trustees University of Illinois Pass-Through 10.310 2015-06396-01 7,772
Subtotal for United States Department of Agriculture -Pass-Through 21,718
Total for United States Department of Agriculture 25,226
11 United States Department of Commerce
Using reforecasts and historical observations to assess severe Direct 11.468 NA16NWS4680008 96,361
weather threat in the extended forecast period
Subtotal for United States Department of Commerce -Direct 96,361
S C Sea Grant consortium Pass-Through 11.431 NA15OAR4310111 15,310
The Texas A&M University System Pass-Through 11.999 SUBAWARD NO. 16-43 9,759
Subtotal for United States Department of Commerce -Pass-Through 25,069
Total for United States Department of Commerce 121,430
12 United States Department of Defense
Investigation of Similitude and Distortion in Large-Scale moveable Bed Direct 12.000 W912P9-14-P-1139 5,157
Models View
Colorectal Cancer Immunotherapy by Pharmacological Suppression of Direct 12.420 W81XWH-16-1-0333 96,469
Liver X Receptor Activity
Connecting the DNA replication fork instability with novel Direct 12.420 W81XWH-16-1-0377 200,106
chemotherapeutic strategies
Evidence-Based Multimodal Neurodiagnostic Imaging of Traumatic Brain Direct 12.420 W81XWH0820191 -2,126
Injury and Post-Traumatic Stress Disorder at SANIC
Peripherally Restricted to REV-ERB Agonists for Treatment of Diabetes Direct 12.420 W81XWH-16-1-0235 192,361
and Obesity
Thromboelastography (TEG) and Platelet Mapping (PM) Patterns in W81XWH-16-1-0236 87,413
7 (Continued)
Awards Subtotal
Passed By Cluster/
Research and Development Cluster (Continued)

12 United States Department of Defense (Continued)
Traumatic Brain Injury Direct 12.800 FA8650-15-2-6J01 8,658
Subtotal for United States Department of Defense -Direct 582,881
Emory University Pass-Through 12.000 T506377 10,903

Pass-Through 12.000 T679658 9,027
Indiana University Pass-Through 12.000 BL-4326920-SLU 6,548
University of Maryland Baltimore Office of Research and Dev Pass-Through 12.000 1701242 PO#SR00004535 17,519
University of Portsmouth Higher Education Corporation Pass-Through 12.000 14775 23,449
Johns Hopkins Bloomberg Pass-Through 12.420 W81WXH1020090 16,541
Subtotal for United States Department of Defense -Pass-Through 83,987
Total for United States Department of Defense 672,025
15 United States Department of The Interior
Operation of the Mid-America Integrated Seismic Network Direct 15.807 G15AC00041, SPPL # 0002 214,933
Subtotal for United States Department of The Interior -Direct 214,933
Curators of the University of Missouri Pass-Through 15.805 C00053653-1 14,717
Subtotal for United States Department of The Interior -Pass-Through 14,717
Total for United States Department of The Interior 229,650
16 United States Department of Justice
Immunological Profiling to Distinguish Virus (Monkeypox) Infection from Direct 16.000 DJF-15-1200-P-0001007 552,214
(Smallpox)
DJF-16-1200-D-0001356 31,710
Subtotal for United States Department of Justice -Direct and Total for CFDA Number 16.000 583,924
Total for United States Department of Justice 583,924
20 United States Department of Transportation
2016 St. Louis Summer Transportation Institute Direct 20.205 PROJECT NO. OJT FY16001 13,978
2017 St. Louis Summer Transportation Institute Direct PROJECT NO. OJT FY 17001 5,087
Erosion Control Blanket Workshop Training Direct 20.215 TR201715 3,981
Subtotal for United States Department of Transportation -Direct 23,046
8 (Continued)
Awards Subtotal
Passed By Cluster/

20 United States Department of Transportation (Continued)
Board of Trustees University of Illinois Pass-Through 20.205 2011-05776-25 233

2011-05776-32 -302 -252
Subtotal for United States Department of Transportation -Pass-Through and Total for CFDA Number 20.205 -69 -252
Total for United States Department of Transportation -252 22,977
43 National Aeronautics and Space Administration
AQAST-Studies of the Relationship between Satellite-Derived Trace Gas Direct 43.000 NNX11AJ63G 83,742
Measurements and Surface Observations: A Proposal for Membership an..
Participation in Tropospheric Emissions: Monitoring of Pollution: Direct 43.000 SV3-83017 15,881
(TEMPO) Program
Subtotal for National Aeronautics and Space Administration -Direct and Total for CFDA Number 43.000 99,623
Mission Success in Cubesats: Improving the Data Collection Direct 43.008 NNX15AV50G 33,928
Remote Sensing from Unmanned Aerial Systems (UAS) to Support Direct 43.008 00050027-08 1,271
Research and Education
Mission Success in Cubesats: Testing the Failure Hypothesis Direct 43.009 NNX17AJ46G 976
Subtotal for National Aeronautics and Space Administration -Direct 36,175

00050287-02 16,178
Subtotal for National Aeronautics and Space Administration -Pass-Through and Total for CFDA Number 43.008 19,523
Total for National Aeronautics and Space Administration 155,321
45 National Endowment of the Arts
Missouri Humanities Council - PAEP 2015 Direct 45.129 1884 -1
Subtotal for National Endowment of the Arts -Direct -1
St Mary's University Pass-Through 45.169 HK-250616-16 3,844
Subtotal for National Endowment of the Arts -Pass-Through 3,844
Total for National Endowment of the Arts 3,843
47 National Science Foundation
Collaborative Research: Investigation of Material Removal in Impact Direct 47.041 1562533 21,252
Machining by Loose Abrasives
GOALI/Collaborative Research: Human Maintenance - A Prognostics Direct 47.041 1634992 7,435
Framework to Model Changes in Drivers' Safety Performance
I-CORPS L: Real-Time Graphical Presentation for Visually Impaired STEM Student Direct 47.041 1632787 778
9 (Continued)
Awards Subtotal
Passed By Cluster/

47 National Science Foundation (Continued)
CAREER: Emergent reactive properties of far-from-equilibrium Direct 47.049 CHE0955555 -4,540

electrochemical systems
CAREER: Photoactive atomic oxygen precursors for the rapid, selective Direct 47.049 CHE-1255270 76,046
oxidation of biological thiols to sulfenic acids
CGV: Small: Collaborative Research: Theories, algorithms, and Direct 47.049 IIS-131944 14,262
applications of medial forms for shape analysis
Chemical Connectomics: Nonlinear Dynamics of Electrochemical Reaction Direct 47.049 1465013 122,864
Networks
Computational Tools for Dynamical Systems Direct 47.049 1602300 41,482
MRI: Acquisition of an ICP Optical Emission Spectrometer for a Diverse Direct 47.049 1626501 74,308
Range of Scientific Applications in Greater Saint Louis
Nonlinear Geometry of Banach Spaces and Metric Spaces Direct 47.049 DMS-1301591 15,455
NSF: DMS: Workshops for Women in Shape Analysis in Turkey Direct 47.049 1619759 6,356
Collaborative Research: Northern Embayment Lithosphere Experiment Direct 47.050 EAR1053363 57,800
(NELE)
Collaborative Research: Wabash Valley Seismic Experiment Direct 47.050 EAR-1249701 42,350
Supplemental funds to enhance United States graduate student Direct 47.050 1613904 9,185
participation at River Flow 2016
Accelerating Human Microbiome Analysis using Lighting-Fast Cloud Direct 47.070 156692 53,180
Computing
AF: Small: Extending algorithms for topological notions of similarity Direct 47.070 1614562 26,001
CAREER: Generalizing Planar Algorithms Direct 47.070 CCF-1054779 46,549
CHS: Small: Collaborative Research: Increasing Social Connectedness in Direct 47.070 1618926 45,216
Telerobotic Platforms through Adding Gesture Capabilities
Collaborative Research: Resilient Virtual Path Management for Scalable Direct 47.070 1647084 18,112
Data-intensive Computing at Network-Edges
STEM Literacy through Infographics Direct 47.070 IIS-1441471 67,427
2016 Plant Cell Dynamics Meeting Nanoscale Imaging to Quantitative Direct 47.074 1640932 11,317
Phenomics
CAREER: Integrative Physiology of Anoxia Tolerance in Turtles Direct 47.074 IOS-1253939 126,647
Collaborative Research: ABI Development: HydroClim: Empowering Direct 47.074 1564896 106,267
aquatic research in North America
NSF IOS #7690676: Genetic change and genetic accommodation allow Direct 47.074 1656818 13,416
singing insects
RESEARCH-PGR: Adapting perennial crops for climate change: Graft Direct 47.074 1546869 136,815 65,473
transmissible effects of rootstocks on grapevine shoots
Total for CFDA Number 47.074 394,462 65,473
DAPPR: Diffusion Analytics for Public Policy Research Direct 47.075 1636695 16,224
Perceptual and Implementation Strategies for Knowledge Acquisition of Direct 47.076 1644538 28,753
Digital Tactile Graphics for Blind and Visually Impaired Students
10 (Continued)
Awards Subtotal
Passed By Cluster/

47 National Science Foundation (Continued)
Bioinformatics Training with Industry Support and Engagement Direct 47.076 1564894 6,357
Bioinformatics Training with Industry Support and Engagement
(BITWISE)
Collaborative Research: A National Consortium for Synergistic Direct 47.076 1625222 24,733
Undergraduate Mathematics via Multi-Institutional Interdisciplinary
Collaborative Research: Distributing the load: using the Direct 47.076 DUE-1245410 4,802
Structure-Behavior -Function framework to inform instructional design
Collaborative research: From the learner's perspective: Unpacking the Direct 47.076 DRL-1420320 60,145
why and how of model-based learning about biological systems.
Total for National Science Foundation-Direct 1,276,994 65,473
JLG Innovations d/b/a ViTAL Pass-Through 47.041 320776 22,725
Georgia Tech Pass-Through 47.049 RG173-G8 32,295

University of California San Diego Pass-Through 47.049 60585079 18,035
University of Notre Dame du Lac Pass-Through 47.075 202435 -1,627
Curators of the University of Missouri Pass-Through 47.079 PROJECT NO. 00052854-2 64,021
Total for National Science Foundation-Pass-Through 282,874
Total for National Science Foundation 65,473 1,559,868
64 Department of Veterans Affairs
A Virtual Pediatric Simulator for Emergency Scenario Training of Military Direct 64.000 N00014-14-0046 3,497
Medica
Colonoscopy vs Fecal Immunochemical Test in Reducing Mortality from Direct 64.000 6576D0017 21,106
Colorectal Cancer ( CONFIRM)
IPA Agreement Direct 64.000 6576D0068 2,164
6577D0005 78,676
6756D0018 7,554
320757 3,919
PO# 657-6D0048 -5,519
PO# 6576D0012 -362
PO# 6577D0046 50,910
PO# 6577D0060 16,734
Subtotal for Department of Veterans Affairs -Direct and Total for CFDA Number 64.000 178,679
Total for Department of Veterans Affairs 178,679
11 (Continued)
Awards Subtotal
Passed By Cluster/

66 Environmental Protection
Evaluation of Bringing as Chloride Best Management Practice (BMP) in St. Louis Region Direct 66.440 97755501 53,245
Midwest Clean Air Stewardship: Building upon the St. Louis Ozone Direct 66.951 97754101 46,536 30,844
Gardens
Subtotal for Environmental Protection -Direct 99,781 30,844
Total for CFDA Number 66.951
Total for Environmental Protection 30,844 99,781
81 United States Department of Energy
Subtotal for United States Department of Energy -Pass-Through
Washington University Pass-Through 81.089 WU-16-107 4,021
Subtotal for United States Department of Energy -Pass-Through 34,218
Total for United States Department of Energy 34,218
84 Department of Education
Lafayette Parish School system Pass-Through 84.334 ERS# 19313 56,586
Subtotal for Department of Education -Pass-Through and Total for CFDA Number 84.334 56,586
Total for Department of Education 56,586
93 Department Of Health And Human Services
6E-11-0033 Vaccine and Treatment Evaluation Units (VTEUs): Evaluation Direct 93.000 HHSN272200800003C 236,408
of Control Measures Against Diseases Other Than AIDS
6G-11-0021 Vaccine and Treatment Evaluation Units (VTEUs): Evaluation Direct 93.000 HHSN272200800003C 599
7C-13-0033-Vaccine and Treatment Evaluation Unit Direct 93.000 HHSN272200080003C 1,070
7D-13-0034 Vaccine and Treatment Direct 93.000 HHSN272200800003C 6,489
8A-09-0065 - Vaccine and Treatment Evaluation Units (VTEUs): Evaluation Direct 93.000 HHSN272200800003C 17,224
9A-12-0096- Vaccine and Treatment Direct 93.000 HHSN272200800003C 10,351
10D-11-0033 Vaccine and Treatment Evaluation Units (VTEUs): Evaluation Direct 93.000 HHSN272200800003C 87,747
10E-12-0106 Vaccine and Treatment Evaluation Units (VTEUs): Evaluation Direct 93.000 HHSN272200800003C 20,436
of Control Measures Against Diseases Other Thand AIDS
11-0033 Lab Assays Direct 93.000 HHSN27200018 2,238
11-0033 Trial Direct 93.000 HHSN272000018 7,697
11E-11-0033L Vaccine and Treatment Evaluation Units (VTEUs): Direct 93.000 HHSN272200800003C 11,631
Evaluation of Control Measures Against Diseases Other Than AIDS
12-0096 Substudy Direct 93.000 HHSN27200018 175
14-0107 Task Area C Option 1 Protocol Implementation Direct 93.000 14-0107.B1C1D1.0023 338,077
12 (Continued)
Awards Subtotal
Passed By Cluster/

93 Department Of Health And Human Services (Continued)
14-0107 Task Area C-2 Protocol Implementation Direct 93.000 14-0107.B1C1D1.0023 253,476
14-0107 Task Area C-3 Protocol Implementation Direct 93.000 14-0107.B1C1D1.0023 202,250
14-0112 Task Area B - Base Protocol Implementation Direct 93.000 14-0112.B1C1D1.0029 6,481
14-0112 Task Area D-7 Direct 93.000 14-0012.B1C1D1.0029 9,250
15-0064 Task Area C - Base Protocol Implementation Direct 93.000 15-0064.C1.0039 341,512
15-0066 B Avian Flu ASO Direct 93.000 15-0066.B1C1D1.0041 14,743
15-0066 C-1 Avian Flu ASO Direct 93.000 15-0066.B1C1D1.0041 469,239
16-0033 Zika in PR, Task Area B-2 Direct 93.000 16-0033.B1C.0046 103,058 33,188
16-0033 ZIka in PR, Task Area C-1 Direct 93.000 16-0033.B1C1.0046 582,791
16-0033 Zika in PR, Task Area C-3 Direct 93.000 16-0033.B1C1.0046 305,490 220,801
16-00333 Zika in PR, Task Area B Base Direct 93.000 16-0033.B1C1.0046 11,668
Description of Supplies/Services: Disaster Health Information Outreach Direct 93.000 HHSN276201500660P 9,233
and Collaboration Project 2015
FY.2015.D1B1C1.0032 01-351 Substudy Direct 93.000 2015.D1B1C1.0032 2,937
FY.2015.D1B1C1.0032 01-643 Substudy Direct 93.000 FY.2015.D1.B1.C1.0032 84,200
FY.2015.D1B1C1.0032 04-0101 Substudy Direct 93.000 FY.2015.D1BC1.0032 20,915
FY.2015.D1B1C1.0032 08-0066 Substudy Direct 93.000 FY.2015.D1B1C1.0032 127,402
FY.2017.AB1C1D1.0048 Task Area A - Base Direct 93.000 FY.2017.A1B1C1D1.0048 278,666
Hamster Model for Human Adenovirus - Task Order A84 Direct 93.000 HHSN272201000021I 699,906
NSABP B-31 A Randomized Trial Comparing the Safety and Efficacy of Direct 93.000 NSABP B-31 67
Adriamycin and Cyclophosphamide Followed by Taxol (AC-t)
Omics A-Base FY.2015.A3D12.0031 Direct 93.000 FY.2015.A3D12.0031 4,569
Omics D-2a FY.2015.A3D12.0031 Direct 93.000 FY2015.A3D12.0031 28,031
Omics D-3a FY.2015.A3D12.0031 Direct 93.000 FY.2015.A3D12.0031 12,677
Omics D-4a FY.2015.A3D12.0031 Direct 93.000 FY.2015.A3D12.0031 2,665
Task Area A - Base - FY.2016.A1B1C1D1.0026 Direct 93.000 FY.2016.A1B1C1D1.0026 21,728
Task Area B Base 16-0004.B1C1D1.0055 Direct 93.000 16-0004.B1C1D1.0055 23,917
Task Area B-2A FY.2017.A1B1C1D1.0048 Direct 93.000 FY.2017.A1B1CD1.0048 26,599
Task Area D-6A FY.2017.A1B1C1D1.0048 Direct 93.000 FY.2017.A1B1C1D1.0048 4,261
Task Area D-6B FY.2017.A1B1C1D1.0048 Direct 93.000 FY.2017.A1B1C1D1.0048 4,413
Task Area D-7A FY.2017.A1B1C1D1.0048 Direct 93.000 FY.2017.A1B1C1D1.0048 14,098
Vaccine and Treatment Evaluation Units (VTEUs): Evaluation of Control Direct 93.000 HHSN272200800003C -30
Measures Against Diseases Other Than AIDS
Zika 16-0017 B Base Direct 93.000 16-0017.B1C1D1.0043 1,647
Zika 16-0017 D-4 Task Area Direct 93.000 16-0017.B1C1D1.0043 386,016 187,955
Total for CFDA Number 93.000 4,794,017 441,944
Mechanistic Insights of BME Mediated Inhibition of Head and Neck Cancer Direct 93.121 1R01DE025141-01 229,010
Growth
Development of RORalpha and RORgamma Ligands for Treatment of Direct 93.242 2R01MH092769-06A1 524,140
Behavioral Disorders
Prescription Opioid Analgesics and Risk and Major Depression 1R21MH101389-01A1 1,166
REV-ERB ligands for treatment of anxiety disorders 7R01MH093429-03 466,263 11,011
Behavioral Health Workforce Education and Training for Professionals Direct 93.243 G02HP27959 181,102
and Paraprofessionals
Subtotal for Department of Health And Human Services -Direct
13 (Continued)
Awards Subtotal
Passed By Cluster/

Using Ecological Momentary Assessment to Define Alcohol's Impact Direct 93.273 R21AA022064 5,150
HIV Outcomes
Subtotal for Department of Health And Human Services -Direct
Exercise: Addressing Stress in Relapse Prevention- Substance Use Direct 93.279 1R01DA033411-01A1 225
Disorders
Exercise: Addressing Stress in Relapse Prevention-Substance Use Direct 4R01DA033411-03 271,289 23,890
Disorders
Preserving opioid analgesia using a novel adenosinergic approach Direct 93.279 1R21DA040305-01 203,781
Apoptosis Regulation by Adenovirus and Cellular Genes Direct 93.393 2R01CA033616 2,124
Breast Cancer Prevention Using Bitter Melon as a Natural Product Direct 1R21CA198382-01 127,210
Human HDAC3: Mechanism of activation and proteasomal degradation Direct 1R21CA178513-01A1 51,261
Implementation Climate in Public Health Settings for Obesity and Cancer Direct 1R03CA172735-01 2,363
Control
Racial Disparity of microRNA in Hepatitis C Virus Mediated Direct 5R21CA188472-02 152,840
Hepatocellularcarinoma
A3AR Agonists to Prevent Chemotherapy-Induced Painful Peripheral Direct 93.395 1R01CA169519-01A1 9,525 44,519
Neuropathy
4R01CA169519-04 520,937 71,455
Gamma/Delta Treg Cells and Human Breast Cancer Direct 93.396 1R01CA184379-01A1 373,800
The Role of Tristetrapolin in Control of Breast Cancer Progression Direct 4R01CA163808-05 202,304
The Role of Tristetraprolin in Control of Breast Cancer Progression Direct 1R01CA163808-01 -9,130
Missouri's State Targeted Response to the Opioid Crisis Direct 93.788 1H79TI080271-01 8,457
Angiotensin receptor regulation by upstream short open reading frames Direct 93.837 410627_GR410606-SLU -1,485
Control of Sterol and Lipoprotein Homeostasis by miRNA Direct 2R01HL107794-06 371,461
PTSD Treatment: Effects on Health Behavior, Cardiovascular and Direct 5R01HL125424-02 495,707 109,975
Metabolic Disease
Structural determination of prothrombin activation (A1 submission) Direct 2R01HL049413-20A1 391,699
Aberrant hematopoiesis: E proteins and AML1-ETO in leukemogenesis Direct 93.839 7R01HL093195-06 -3,648
Protease Activated Signaling by Coagulation Proteases Direct 2R01HL101917-05A1 203,440
Serpin regulation of coagulation proteases Direct 2R01HL062565 56,039
Studies on anticoagulant properties of thrombin Direct 2R01HL073813-11 144,095
14 (Continued)
Awards Subtotal
Passed By Cluster/

A negative feedback loop between Osteoclasts and CD8 T-cells Direct 93.846 1R01AR0642821-01A1 303,948 10,158
ERRgamma Agonists to Treat Muscular Dystrophy Direct 1R01AR069280-01A1 406,887
High Throughput Screening to Identify Small Molecule Rank Agonists Direct 1R01AR068438-01 307,416
Therapeutic application of small molecule MIF inhibitors in rheumatoid Direct 5K01AR060300-02 14,053
arthritis
Glucose transporters and cellular antioxidant potential Direct 93.847 1R15DK102122-01A1 153,150
2017 Biolron Conference Direct 1R13DK113771-01 19,600
Hepatitis C Virus Infection and Mechanism of Liver Disease Progression Direct 1R01DK113645-01 30,250
Innate Immunity and Hepatitis C Virus Infection Direct 5R01DK081817 -7,187
Investigating Synthetic Ligands for the Treatment of NASH Direct 5F32DK105845-03 REVISED 26,460
Mechanisms of Liver Disease Progression by Hepatitis C Virus Direct 5R01DK080812 3,791
Melanocotrin-3 Receptor Regulation of Physical Activity and Metabolism Direct 7R01DK073189-09 33,941
Midwest Hepatitis B Consortium Direct 5U01DK082871-010 400,449 74,537
Mitochondrial Carbonic Anhydrases and Diabetic Blood-Brain Barrier Direct 1R01DK08348501 21
Disruption
Regulation of Nephron Progenitor Cell Self-Renewal and Differentiation Direct 1R01DK098563-01A1 347,587
Regulatory Role of Transferrin in Erythropoiesis and Iron Metabolism Direct 1R01DK095112-01A1 168,141 141,068
Stable isotopic and metabolic studies in a model of lactic acidosis Direct 1R15DK097700-01 59,730
tolerance
The Role of EBI3 in Regulating Gastritis and Gastric Carcinogenesis Direct 1R01DK110406-01 355,876 165,763
The Saint Louis University Component of the NASH Clinical Research Direct 5U01DK061718-16 438,941 128,346
Network
Convergent Versus Parallel Striatal Afferents Direct 93.853 2R01NS023805-24A1 -36,154

Convergent Versus Parallel Striatal Afferents Direct 4R01NS023805-27 304,491
Dissecting the Contribution of Viral Genetic Variation to HSV-1 Direct 1R21NS098104-01 164,502 69,486
Neuropathogenesis
Peripheral Glial Response to Sensory Nerve Degeneration Direct 1R21NS087574-01A1 190,873
Structural studies of PARK14 Direct 1R21NS094854-01A1 189,857
The role of TDP-43 phosphorylation in protein function and Direct 1K01NS082391-01 13,312
neurogdegeneration
A High Throughput Reverse Genetics System for Hepatitis C Virus Direct 93.855 1R03AI111047-01A1 56,623
A screen for antiviral compounds targeting the Hepatitis B Virus Direct 1R01AI104494-01A1 138,330
ribonuclease H
Aspartic Protease Inhibitors as Novel Antimalarials Direct 1R01AI106498-01 66
Assembly of HIV intasomes Direct 1R21AI127196-01 158,880
Biochemistry of Viral Replication Direct 4K06AI004739-51 28,393
Direct 4K06AI004739-55 5,679
Defining approaches for improving HID and HPD compounds as BHV Direct 1R21AI124672-01A1 33,630
RNaseH
Development of a vaccine for prevention of Haemophilus Influenzae otitis Direct 1R01AI081887 47,228
media
Frequency and pattern of resistance mutations to novel inhibitors of Direct 1R03AI115321-01A1 63,881
HSV-1
Functions in Hopx in Immune Tolerance in a Model of Multiple Sclerosis Direct 1R01AI113903-01 420,054
Hepatitis B Virus Diversity and Ribonuclease H Inhibitor Efficacy Direct 93.855 1R03AI109460-01A1 7,613
Immune Control of West Nile Virus Quasispecies Dynamics Direct 1K22AI04794-01A1 142,998
15 (Continued)
Awards Subtotal
Passed By Cluster/

Mechanisms of IL28B Genetic Variation- Mediated Clearance of Hepatitis Direct 1R21AI099780-01A1 39,227
C Virus
Next Generation Sequencing based on analysis of RNA polymerase Direct 1R21AI112919-01A1 115,456
functions
Optimization of alpha-hydroxytropolones as novel inhibitors of the HBV Direct 1R01AI122669-01 411,700 137,514
RNaseH
Protective and pathologic effects of Th17 cells specific for an intracellular Direct 1R21AI128270-01 60,149
pathogen
R21 Resubmission: Viral Categorization and Discovery in Acute Liver Direct 1R21AI117128-01A1 63,581
Failure and Unknown Etiology
Role of gamma/delta T cells in vaccine induced immunity Direct 2R01AI048391-09 285,369 132,234
T cell Activation by Immune Complexes and complement in Autoimmunity Direct 4R01AI098114-05 302,665
Structural studies of the HBV ribonuclease H Direct 93.856 1R03AI123689-01 56,705

Task Order 006: DMID13-0069 ECG Lab Work Direct HHSN272200800026C, CEL-11-01 10,049
Biomimetic Platform for Metabolomic Analysis Direct 93.859 1R15GM113153-01 97,657

Chlorinated Lipids in Sepsis Direct 1R01GM115553-01 513,713 179,355
Cohesion and Enhancers Direct 1R01GM108714-01A1 229,526
Cohesion Polycomb Direct 1R01GM108872-01 305,139
Identification of DNA apatazymes for small molecule-sensors Direct 1R15GM101595-01 -491
Mechanisms Responsible for Genomic Instability in Premature Aging Direct 7R01GM094513-03 401
Laminopathies
Microchip-based Cell Reactor/Analysis System Direct 2R15GM084470-04A1 85,170
New bioanalytical methods based on next generation sequencing Direct 1R01GM109974-01A1 311,779
New Mechanisms in Regulating Ras and Protein Kinase A Signaling Direct 1R15GM1060330-01 50,148
New Mechanisms of Replication Stress Response Direct 1R01GM108648-01 297,619
Pharmacological Sciences Training Grant Direct 5T32GM008306-227 REVISED 139,832
Understanding the thermodynamics and structure of RNA secondary Direct 2R15GM085699-03 36,376
structure motifs
Newborn Screening and Biomarkers for Mucopolysaccharidoses Direct 93.865 1R01HD065767-01A1 158,693 158,405
A Big Data Research Study on the Relationship Between Metformin Use Direct 93.866 R21AG055604 13,585
and Dementia
Colonoscopy in Colorectal Cancer Patients with Multiple Chronic Direct 1R56AG049503-01A1 34,854 -3,096
Conditions (R56)
Investigation of neural mechanisms of late life cognition and emotion Direct 7K01AG049075-02 96,374
regulation
Total for CFDA Number 93.866 144,813 -3,096
Pediatric Eye Disease Investigator Group Coordinating Center 93.867 2U10EY011751 6,413
16 (Continued)
Awards Subtotal
Passed By Cluster/

Academic Administrative Units in Primary Care 93.884 D54HP232860400 54,243

Residency Training in Primary Care D58HP23229-04 29,467
Subtotal for Department of Health and Human Services-Direct 18,573,851 1,896,564
Board of Trustees of Southern Illinois University Pass-Through 93.000 761820-001 2,267

Pass-Through 761820-001-02 27,561
Clinical Research Management Inc Pass-Through CEL-11-01 13,433
Curators of the University of Missouri Pass-Through 00054922-2 23,793
Emory University Pass-Through T649571 225,488
National Surgical Adjuvant Breast and Bowel Project Pass-Through NSABP B-30 290
Pass-Through NSABP B-36 982
National Surgical Adjuvant Breast and Bowel Project Pass-Through NSABP B-40 786
Pass-Through NSABP B-46 3,476
PaxVax Inc Pass-Through PXVX-PA-0001- -1,339
Southwest Oncology Group Clinical Trials Initiative LLC Pass-Through CALGB 80405 1,241
Pass-Through CTSU/C10404 32
Pass-Through S0702 4,143
Pass-Through S0931 413
Pass-Through S1106 1,658
Pass-Through SWOG S0120 690
Washington University Pass-Through WU-17-5 43,526
University of Texas Health Science Center - Houston Pass-Through 93.080 0011472K 6,605
University of Texas Health Science Center - Houston Pass-Through 0011472M 16,510
Pass-Through AMEND #1 SUBAWARD 0011472K 15,663
University of Kansas Medical Center Pass-Through 93.103 QB859730 12,709

University of Texas Health Science Center - Houston Pass-Through AMEND 5, SUB 0010176E 26,832
Pass-Through SUB #0010176M, H30MC24051-05 23,350
Board of Trustees for the University of Alabama Pass-Through 93.113 000501087-001 162,940
Pass-Through 000507395-001 156,728
Pass-Through 000510923-001 93,082
West Virginia University Pass-Through 93.136 04-441-SLU 13,316
17 (Continued)
Awards Subtotal
Passed By Cluster/

NorthShore University HealthSystem Pass-Through 93.226 EH14-422 8,409
University of Iowa Pass-Through 93.262 PO#: 1001559504 2,073

Pass-Through W000870562/PO1001763.. 17,616
Washington University Pass-Through 93.273 WU-14-149-MOD-3 76,481
Subtotal for Department of Health And Human Services -Pass-through 76,481
Johns Hopkins University Pass-Through 93.286 2002785144 7,693

Michigan State University Pass-Through RCI030565SLU -52
Washington University Pass-Through 93.350 WU-16-12 PO 2928044A 338

Pass-Through WU-16-16 PO#2928045A -705
Total for CFDA Number 93.350 -367
University of Maryland Pass-Through 93.393 Z035601 32,836
Children's Hospital of Philadelphia Pass-Through 93.395 9500080215-12C 9,285

John Wayne Cancer Institute at Saint Johns Health Center Pass-Through 308801 2,059
University of Iowa Pass-Through W000762480- PO #1001533466 7,664
Pass-Through W000864431/PO1001692.. 85,377
Brigham & Women's Hospital Pass-Through 93.837 PS #107223 11,061

Duke University Pass-Through 203-8159 69,715
Pass-Through 193603 -4,198
Pass-Through 200464 -2,817
Pass-Through AMEND #1 SUB 203-8799 106,696
Pass-Through EPM 6718 32
Pass-Through SUB 2038823 AMEND #1 13,237
Pass-Through SUBAWARD 203-8180 10,333
Emory University Pass-Through T594891 AMEND #2 70,386
Emory University Pass-Through T763920 (T594891), AMEND #3 36,636
Georgetown University Pass-Through 410627_GR410606, MOD 2 367,123
Pass-Through GR411196_GR411104, MOD 1 62,231
New York University School of Medicine Pass-Through 10-01073 4,915
Pass-Through 10-01703,PO# M160048763 3,660
Washington University Pass-Through SUB# WU-17-346, PO# 2928738C 7,424
Pass-Through WU-16-279, PO# 2929011A 3,633
18 (Continued)
Awards Subtotal
Passed By Cluster/

Pass-Through WU-16-280, PO# 2929012A 8,609

Pass-Through WU-16-384 214,165
Pass-Through WU-17-341 PO# 2928783C 3,239
Case Western Reserve University Pass-Through 93.838 RES508387 61,068

Seattle Childrens Hospital Pass-Through 10928SUB 10,204
Rutgers The State University Pass-Through 93.839 320908 3,966

Pass-Through SUBAWARD #0027, PO # 548662 33,989
Board of Trustees University of Illinois Pass-Through 93.846 16285 12,568

George Washington University Pass-Through SUBAWARD #13-D21 18,208
Pass-Through SUBAWARD #15-D10 20,719
Pass-Through SUBAWARD# 14-D10 152,891
Johns Hopkins University Pass-Through 93.847 PO# 2003402850 138,612

National Institute of Diabetes & Digestive & Kidney Diseases Pass-Through 1K08DK098623-01A1 143,176
Pass-Through 1R01DK106249-01 276,610
Pass-Through 5R01DK081817-07 288,175
Pass-Through 5U01DK061718-16 -7,566 10,199
Pass-Through 5U01DK082871-010 -21,091
Nuero 10-9 Pharma Inc Pass-Through ERS# 19451 28,826
Research Institute at Nationwide Childrens Hospital Pass-Through AMENDMENT 2 SUB 952615 1,061
University of Cincinnati Pass-Through 009621-002 37,334
Washington University Pass-Through AM3 WU-15-65-MOD-2, PO#29223 25,463
Pass-Through WU-13-184/PO#2917222W 1,057
Pass-Through WU-15-130-MOD 3, PO #2922554Y 130,581
Fred Hutchinson Cancer Research Center Pass-Through 0000848398 10,471
Pass-Through 0000885177 45,897
Los Angeles Biomedical Research Pass-Through 20954-SLU PO#16007680 11,089
Mayo Clinic Jacksonville Pass-Through 320633 2,000
Regents of the University of Minnesota Pass-Through N004688803 25,455
Fred Hutchinson Cancer Research Center Pass-Through SUB #0000851954, PRJ #214241 2,796
Pass-Through SUBAWARD 0000887524 8,437
George Washington University Pass-Through 16-S06 37,130
Kansas State University Pass-Through S15011.01 10,540
Mediomics LLC Pass-Through ERS# 40709 25,250
MediSynergics LLC Pass-Through ERS# 19853 24,573
Northeastern University Pass-Through 93.855 500469-78050 85,490

Pass-Through UPDATE WITH FEA 3,683
Pennsylvania State University Pass-Through #5231-SLU-DHHS-5818 21,693
Regents of the University of California San Francisco Pass-Through 8465 -2,400
Pass-Through 8465C 2,400
19 (Continued)
Awards Subtotal
Passed By Cluster/

University of Oklahoma Post Award Financial Services Pass-Through SUBCONTRACT #2015-10 73,766
Washington University Pass-Through WU-14-358-MOD1 11,659
Subtotal for Department of Health And Human Services -Pass-through
Division of General Medical Pass-Through 93.859 1R01GM112188-01A1 253,467

DNA Polymerase Technology Inc Pass-Through 320502 35,307
Regents of the University of Minnesota Pass-Through H003737501 21,723
Pass-Through H005083801 88,616
University of Cincinnati Pass-Through COEUS #008601-006 36,937
Children's Hospital of Philadelphia Pass-Through 93.865 ACTIVITY #3017X 16,389

Childrens Hospital Medical Center Pass-Through 130245 AMENDMENT #3 95,403
Pass-Through 130245, PO #3100417358 -6,174
Pass-Through SUBAWARD NO. 136785 9,234
Rectors and Visitors of the University of Virginia Pass-Through GB10318 152738 AMEND #1 758
University of Houston Pass-Through R-12-0058 9,036
Board of Trustees of Southern Illinois University Pass-Through 93.866 SUBAGREEMENT #761815-002 56,612
Seattle Institute for Biomedical & Clinical Research Pass-Through BW29-SLU-3 70,719
Pass-Through BW29-SLU-4 10,969
University of California Pass-Through 64946772 24,917
Pass-Through 68213713, AMEND1, PO S9001267 39,852
University of Iowa Pass-Through W000729883 PO 1001496890 11,387
Washington University Pass-Through WU-15-328 4,853
Children's Hospital of Philadelphia Pass-Through 93.867 3209850815 1,838

Pass-Through AMEND #5, SUB 3209850817 7,251
Missouri Department of Health & Senior Services Pass-Through CS171489002 271
Subtotal for Department of Health and Human Services-Pass-Through 4,928,699 10,199
Total for Department of Health and Human Services 1,906,763 23,502,550
United States Agency for International Development

International Aids Vaccine Initiative Pass-Through 98.001 AGREEMENT #2397 6,854
Subtotal for United States Agency for International Development -Pass-Through 6,854
Total for United States Agency for International Development 6,854
Total Research and Development Cluster 2,002,828 27,252,932
20 (Continued)
Awards Subtotal
Passed By Cluster/
TRIO Cluster
Student Support Services Grants Direct 84.042 P042A151598 256,311
TRIO - Talent Search Direct 84.044 POA44110876 86,325

TRIO-Talent Search Direct 84.044 P044A160669 161,088
Total for TRIO Cluster 503,724
Other Programs
14 United States Department of Housing and Urban Development
St. Louis Housing Authority Pass-Through 14.897 320787 35,275
Subtotal for United States Department of Housing and Urban Development -Pass-Through 35,275
Total for United States Department of Housing and Urban Development 35,275
66 Environmental Protection Agency

St Louis Community College Pass-Through 66.815 320431 20,396
320706 42,351
Subtotal for Environmental Protection Agency -Pass-Through 62,747
Total for Environmental Protection Agency 62,747
84 Department Of Education
St Louis Public Schools Foundation Pass-Through 84.215 Null 24,532
Q215F120077 20,881
Subtotal for Department of Education -Pass-through 45,413
Total for Department of Education 45,413
93 Department Of Health And Human Services

Area Health Education Centers Point of Service and Enhancement Direct 93.107 U77HP23070--06-00 106,745 78,989
Subtotal for Department of Health And Human Services -Direct 106,745 78,989
Behavioral Health Workforce Education and Training for Professionals Direct 93.243 1G02HP30566-01-00 67,655
and Paraprofessionals
Subtotal for Department of Health And Human Services -Direct 67,655
HRSA - The St. Louis University Urban Undeserved MD/MPH Program Direct 93.884 5T85HP24467-05-00 273,356 58,172
Subtotal for Department of Health And Human Services -Direct 273,356 58,172
Show Me Healthy Women FY 15-18 Direct 93.919 320573 2,374
Public Health Traineeships for Maternal Child Health Direct 93.964 1A03HP27852-01 3,321
21 (Continued)
Awards Subtotal
Passed By Cluster/
Other Programs (Continued)

Gateway Geriatric Education Center Geriatrics Work Force Enhancement Program Direct 93.969 5 U1HP28716-03-00 965,739 292,910
Geriatric Education Centers Direct 5UB4HP19060 -3,897
Genetic Disease Program Services Direct 93.994 C313163001 AMENDMENT 002 48
Subtotal for Department of Health And Human Services -Direct 48 430,071
Total for CFDA Number 93.994 48
Minneapolis Medical Research Foundation Pass-Through 93.000 HRSA-SRTR 4,007
Subtotal for Department of Health And Human Services -Pass-Through 4,007
St Louis County Department of Health Pass-Through 93.069 320230 -63
Subtotal for Department of Health And Human Services -Pass-Through -63
Total for CFDA Number 93.069 -63

Pass-Through WU-17-XXX 24,406

Pass-Through C00056255-1 7,100
Nurses for Newborns Foundation Pass-Through 93.505 HRSA-10-275 20,155

HRSA-13-215 18,014
Kentucky Population Health Institute Pass-Through 93.516 KPHI302 166
Subtotal for Department of Health And Human Services -Pass-Through 166
Total for CFDA Number 93.516 166
Missouri Department of Health & Senior Services Pass-Through 93.752 ERS16116083/41482 1,198
Missouri Department of Health & Senior Services Pass-Through 93.758 320667 6,000
DH160017001 - 5,169
AMEND001
Pass-Through DH160077001 2,348
Health Resources and Services Administration Pass-Through 93.884 1 T0BHP30018-01-00 272,991 67,111
Subtotal for Department of Health And Human Services -Pass-Through 272,991 67,111
22 (Continued)
Awards Subtotal
Passed By Cluster/
Other Programs (Continued)

City of St Louis Pass-Through 93.914 HD CONTRACT #16-46 183,707

HD CONTRACT #17-XX 69,541

WU-17-358 9,104
Missouri Department of Health & Senior Services Pass-Through 93.919 ERS16117073 1,066
Health Resources and Services Administration Pass-Through 93.925 T08HP30219-02-00 600,000
Minneapolis Medical Research Foundation Pass-Through 93.994 HRSA-SRTR 59,478

NRSA-SRTR 82,229
Missouri Department of Health & Senior Services Pass-Through C313163001, 3,291
AMENDMENT 003
Total for Department of Health And Human Services 67,111
Total for Cluster 497,182 2,903,330
Total Other Programs 3,046,765

Grand Total $ 2,500,010 $ 175,359,561
See accompanying independent auditors’ report and notes to schedule of expenditures of federal awards.
23
Notes to Schedule of Expenditures of Federal Awards
(1) Summary of Significant Accounting Policies and Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the Schedule) summarizes the
expenditures of Saint Louis University (the University) under programs funded by the federal government
for the year ended June 30, 2017. The information in this schedule is presented in accordance with the
requirements of Title 2 U.S. Code of Federal Regulations Part 200 Uniform Guidance Administration
Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). The
Schedule has been prepared on the accrual basis of accounting. Because the Schedule presents only a
selected portion of the operations of the University, it is not intended to and does not present the financial
position or changes in net assets of the University.
For purposes of the Schedule, federal awards include all grants and contracts entered into directly between
the University and agencies and departments of the federal government, as well as federal funds passed
through to the University by other recipients.
(2) Indirect Cost Rates

Expenditures for federal programs are recognized using the cost accounting principles contained in the
Uniform Guidance, Subpart E-Cost Principles. Under those cost principles, certain types of expenditures
are not allowable or are limited as to reimbursement. Expenditures include a portion of costs associated
with general University activities (facilities and administrative costs or indirect costs), which are allocated to
federal awards under negotiated formulas commonly referred to as facilities and administrative cost rates.
Facilities and administrative costs allocated to such awards for the year ended June 30, 2017, were based
on predetermined fixed rates up to 51.5% negotiated with the University’s cognizant federal agency, the
U.S. Department of Health and Human Services, and are included as a component of the expenditures in
the Schedule. The University has not elected to use a 10% de minimis cost rate provided for in the Uniform
Guidance.
(3) Loan Programs

The University participates in various loan programs. Certain loan programs are considered to be a
component of the student financial assistance cluster. The following schedule represents loans outstanding
of the University as of June 30, 2017:
CFDA Outstanding
number balance
Federal Perkins Loan Program 84.038 $ 13,855,393

Loans for Disadvantaged Students 93.342 301,183
Primary Care Loans 93.342 2,055,181
Nursing Student Loan Program 93.364 846,282
Nurse Faculty Loan Program – ARRA 93.264 20,741
Nurse Faculty Loan Program 93.264 212,740
Total – Student Financial Assistance Cluster

Loans Outstanding $ 17,291,520
24 (Continued)
Notes to Schedule of Expenditures of Federal Awards
The following schedule represents loans advanced by the University for the year ended June 30, 2017:
CFDA
number Loans advanced
Federal Perkins Loan Program 84.038 $ 2,323,085
Loans for Disadvantaged Students 93.342 36,000
Nursing Student Loan Program 93.364 238,680
Nurse Faculty Loan Program 93.264 63,982
Total – Student Financial Assistance Cluster
Loans Outstanding $ 2,661,747
The University claimed an administrative cost allowance of $177,512 to the Federal Perkins Loan Program
for 2017. The University also claimed an administrative cost allowance of $59,622 on its Federal Work
Study Program during 2017, which is included in the amounts on the Schedule.
25
Schedule of Findings and Questioned Costs
(1) Summary of Auditors’ Results

(a) Type of report issued on whether the consolidated financial statements were prepared in accordance
with generally accepted accounting principles: Unmodified
(b) Internal control deficiencies over financial reporting disclosed by the audit of the consolidated financial
statements:
• Material weaknesses: No
• Significant deficiencies: None Reported
(c) Noncompliance material to the consolidated financial statements: No
(d) Internal control deficiencies over major programs disclosed by the audit:
• Material weaknesses: No
• Significant deficiencies: Yes
(e) Type of report issued on compliance for major programs: Unmodified
(f) Audit findings that are required to be reported in accordance with 2 CFR 200.516(a): Yes
(g) Major programs:
• Research and Development Cluster: Various CFDA numbers

• Student Financial Assistance Cluster: Various CFDA numbers
• Geriatric Education Centers: CFDA 93.969 and Gateway Geriatric Education Centers Workforce
Enhancement Program: CFDA 93.969
(h) Dollar threshold used to distinguish between Type A and Type B programs: $906,103
(i) Auditee qualified as a low-risk auditee: Yes
(2) Findings Relating to the Financial Statements Reported in Accordance with Government Auditing
Standards
None
26 (Continued)
(3) Findings and Questioned Costs Relating to Federal Awards

Finding 2017-001 – Inaccurate Reporting of Federal Expenditures on the Schedule of Expenditures
of Federal Awards (SEFA)
Federal agency US Department of Health and Human Services and

National Science Foundation
Program name Research and Development Cluster
CFDA No. and program expenditures 84.215, 93.964, 93.113, 93.994, 47.074, 93.242, 93.393,
93.846, 93.847, 93.855, 93.859, 93.103, 93.243, 93.273,
93.350
Award numbers Q215F120077, 1A03HP27852-01, 000507395-001,

C313163001, AMENDMENT 003, 1640932,
7R01MH093429-03, 1R21CA178513-01A1,
1R01AR0642821-01A1, 7R01DK073189-09,
1R01AI106498-01, 1R01AI113903-01,
1R03AI109460-01A1, 5T32GM008306-227 REVISED,
QB859730, 000507395-001, 000510923-001,
00050377-1, WU-14-149-MOD-3, WU-16-16
PO#2928045A, WU-14-358-MOD1,
1R01GM112188-01A1, 320502
Federal award years 7/1/16 – 6/30/17
Condition Found
Saint Louis University (the University) did not have effective internal controls in place to accurately report
Federal expenditures on the Schedule of Federal Awards (SEFA) under the Research and Development
Cluster (R&D), specifically the Allergy and Infection Diseases Research, Mental Health Research Grants,
Musculoskeletal and Skin Diseases Research, Cancer Cause and Prevention Research, Diabetes,
Digestive, and Kidney Diseases Extramural Research, and Biological Sciences programs. Specifically, the
supervisory review was not at an appropriate level of precision to identify misclassifications.
27 (Continued)
Federal expenditures reported on the initial draft of the SEFA did not agree to the University’s financial
records. Certain grants related to the R&D cluster were misclassified. Specifically, we noted the following
differences for the year ended June 30, 2017, which were corrected by management on the final SEFA:
R&D
Amounts R&D
previously Actual Overstatement/
Program CFDA No. reported amount (understatement)
St. Louis Public Schools

Foundation 84.215 $ 45,413 $ — $ 45,413
Public Health Traineeships
for Maternal Child Health 93.964 3,321 — 3,321
Missouri Department of
Health & Senior Services 93.994 3,291 — 3,291
2016 Plant Cell Dynamics
Meeting Nanoscale Imaging
to Quantitative Phenomics 47.074 — 11,317 (11,317)
REV-ERB ligands for
treatment of anxiety
disorders 93.242 — 466,263 (466,263)
Human HDAC3: Mechanism
of activation and proteasonal
degradation 93.393 — 51,261 (51,261)
A negative feedback loop
between Osteoclasts and
CD8 T-cells 93.846 — 303,948 (303,948)
Melanocotrin-3 Receptor
Regulation of Physical
Activity and Metabolism 93.847 — 33,941 (33,941)
Aspartic Protease Inhibitors
as Novel Antimalarials 93.855 — 66 (66)
Functions in Hopx in Immune
Tolerance in a Model of
Multiple Sclerosis 93.855 — 420,054 (420,054)
Hepatitis B Virus Diversity
and Ribonuclease H Inhibitor E
cacy 93.855 — 7,613 (7,613)
Pharmacological Sciences
Training Grant 93.859 — 139,832 (139,832)
University of Kansas Medical
Center 93.103 — 12,709 (12,709)
Board of Trustees for the
University of Alabama 93.113 — 156,728 (156,728)
Board of Trustees for the
University of Alabama 93.113 — 93,082 (93,082)
Curators of the University of
Missouri 93.243 — 89,822 (89,822)
28 (Continued)
Amounts Actual Overstatement/

Program CFDA No. reported amount (understatement)
Washington University 93.273 $ — $ 76,481 $ (76,481)
Washington University 93.350 — (705) 705
Washington University 93.855 — 11,659 (11,659)
Division of General Medical 93.859 — 253,467 (253,467)
DNA Polymerase Technology
Inc 93.859 — 35,307 (35,307)
Total $ 52,025 $ 2,162,845 $ (2,110,820)
Criteria or Requirement
According to 2 CFR 200.510(b), a recipient of federal awards is required to prepare a SEFA for the period
covered by the entity’s financial statements which must include the total Federal awards expended. At a
minimum, the schedule must include (1) a list of individual Federal programs by Federal agency. For
Federal programs included in a cluster of programs, list individual Federal programs within a cluster of
programs; (2) for Federal awards received as a subrecipieint, the name of the pas-through entity and
identifying umber assigned by the pass-through entity shall be included; (3) provide total Federal awards
expended for each individual Federal program and the CFDA number or other identifying number when the
CFDA information is not available; (4) include total amount provided to subrecipients for each Federal
Program; and (5) includes notes that describe the significant accounting policies used in preparing the
SEFA.
In addition, 2 CFR 200.303 requires nonfederal entities to, among other things, establish and maintain
effective internal control over the Federal awards that provides reasonable assurance that the non-Federal
entity is managing the Federal awards in compliance with Federal statutes, regulations, and the terms and
conditions of the Federal awards. Effective internal controls should include procedures to ensure
expenditures and amounts passed through to subrecipients are properly reported on the SEFA.
Cause
In discussing the condition with University management, they stated that the initial errors in the Federal
expenditures reported on the SEFA were due to oversight and misunderstanding of what was required to
be reported.
Possible Asserted Effect

Failure to accurately report federal expenditures prohibits the completion of an audit in accordance with the
Uniform Guidance, which may result in the suspension of Federal funding. Additionally, the completeness
and accuracy of the SEFA is critical in reporting the proper amount of Federal expenditures during a fiscal
year.
Questioned Costs
None
29 (Continued)
Repeat Finding
Yes
Statistical Sampling
The sample was not intended to be, and was not, a statistically valid sample.
Recommendation
We recommend the University review its current internal control procedures to ensure the SEFA is
accurately prepared and reflects the Federal expenditures relating to the correct accounting/fiscal period.
Views of University Management

The University concurs with the recommendation and will develop procedures to accurately report Federal
expenditures on the SEFA in the current accounting period and ensure amounts are supported by financial
activity in the general ledger. Accounting personnel have been trained and instructed in modified
procedures to properly record Federal expenditures.

The University concurs with the recommendation and will develop procedures to accurately prepare the
SEFA.
30 (Continued)
Finding 2017-002 – Equipment & Real Property Management

Federal agency U.S. Department of Health and Human Services and
National Science Foundation
Program name Research and Development Cluster
CFDA No 93.855, 93.242, 93.846, 93.393, 93.847, and 47.074
Award numbers 1R01AI106498-09, 1R01AI113903-01,

1R03AI109460-01A1, 7R01MH093429-03,
1R01AR0642821-01A1, 1R21CA178513-01A1,
7R01DK073189-09, and 1640932
Federal award years 2016-2017
Condition Found
One equipment asset (valued at $65,560) out of the 25 assets selected for physical observation was no
longer in the possession of the University at the date of our testing (February 19, 2018). Total equipment
assets held by the University-sponsored programs was approximately $6 million at June 30, 2017.
Criteria or Requirement
2 CFR section 200.313 requires that property records must be maintained which include a description of
the property, a serial number or other identification number, the source of funding for the property, who
holds title, the acquisition date, and cost of the property, percentage of Federal participation in the project
costs for the Federal award under which the property was acquired the location, use and condition of the
property, and any ultimate disposition data including the date of disposal and sale price of the property. A
physical inventory of the property must be taken and the results reconcile with the property records at least
once every two years.
In addition, 2 CFR 200.303 requires non-federal entities to among other things establish and maintain
effective internal control over the federal award that provides reasonable assurance that the non-federal
entity is managing the federal award in compliance with federal statutes, regulations, and the terms and
conditions of the federal awards. Effective internal controls should include establishing and maintaining
adequate controls over equipment inventory.
Cause
The University performs annual physical inventory procedures. However, the inventory internal control
procedures failed to detect a missing asset. This selected item was not noted during the University’s
verification process that it was no longer part of the University’s equipment. The item selected for testwork
was removed from University’s property by a principal investigator that left the University during 2014.
31 (Continued)
Possible Asserted Effect

Failure to report dispositions of equipment to the U.S. Department of Health and Human Services and
National Science Foundation could result in inaccurate property and equipment records.
Questioned Costs
None
Repeat Finding
No
Statistical Sampling
The sample was not intended to be, and was not, a statistically valid sample.
Recommendation
We recommend the University establish procedures to timely report dispositions of assets to the Federal
Government.

The University concurs with the recommendation and will develop procedures to report dispositions of
assets to the Federal Government.
32
January 12, 2018
KPMG LLP
10 South Broadway
Suite 900
ASSOCIATE VICE
St Louis, MO 63102
PRESIDENT FOR
RESEARCH Ladies and Gentlemen:
3700 West Pine Mall
Fusz Memorial Hall This is to document the completion of our corrective action plan for finding 2016-001 –
Room 255 Inaccurate Reporting of Federal Expenditures on the Schedule of Expenditures of
St. Louis, MO 63108
Federal Awards (SEFA).
P 314-977-2047
F 314-977-2026
mchristian@slu.edu
Specifically, KPMG found that the University did not accurately report Federal
expenditures on the Schedule of Expenditures of Federal Awards (SEFA) under the
www.slu.edu Student Financial Assistance Cluster, specifically the Federal Perkins Loan Program,
Direct Loan Program, Nurse Faculty Loan Program, Primary Care Loans, Loans for
Disadvantaged Students and Nursing Student Loan Program.
All staff who contribute to the creation of the SEFA were retrained in April 2017 and
were provided with the attached procedural document. Because financial aid was still
working when a draft SEFA was requested in August, correct numbers for these entries,
including the correct ACA were confirmed in late December. SLU’s final SEFA reflects the
new procedure.
Sincerely yours,
Matthew Christian
Associate Vice President for Research
Higher purpose. Greater good.

Requirement(s) for Annual SEFA Reporting on Student Loans

The default method for reporting on federal awards is expenditures within the fiscal year. Because we typically recognize revenue
associated with the academic year, we need to calculate fiscal year expenditures when reporting on the SEFA.

For DIRECT LOANS: Pull the standard report and total by year and type in a Pivot Table

This report was downloaded from Banner by Janice Barnes, SFS. Parameters used to run the report were the fiscal year dates (7/1/15 - 6/30/16) with no filters for academic year
Saint Louis University
Prepared By: Student Financial Services
Prepared On: Nov 3, 2016
All Federal Aid - 20150701 through 20160630
Report Name: ADHOCRQ
Name SID ACADEMIC_YEAR DL-SB DL-UN DLG DLPG DLPLUG DLPLUS DLPS DLSB DLU DLUA DLUN Total Direct Loan HRSAC PELL PERKINS SEOG TOTAL
Abady, Josephine P. 000453360 2016 .00 3,625.00 3,625.00
Abatso-Diaz, Toya Y. 000741342 2016 20,282.00 20,282.00 20,282.00
Abbaraju, Anuhya S. 000777051 2016 3,464.00 1,980.00 5,444.00 5,444.00
Abbott, Philip W. 000074039 2016 9,379.00 758.00 10,137.00 10,137.00
Abdolrazagh, Arika 000772439 2016 4,452.00 3,958.00 1,980.00 10,390.00 5,775.00 4,000.00 20,165.00
Abdullaeva, Albina 000494777 2016 5,442.00 6,926.00 12,368.00 4,000.00 16,368.00
Abdullaeva, Sabina 000732942 2016 5,442.00 1,980.00 7,422.00 4,325.00 4,000.00 15,747.00
Abdullaeva, Susana 000747995 2016 5,442.00 6,926.00 12,368.00 3,610.00 15,978.00
Abdulqader, Roz M. 000502062 2016 5,442.00 5,442.00 5,775.00 4,000.00 4,000.00 19,217.00
Abedsaidi, Babak 000716883 2016 4,452.00 1,980.00 6,432.00 5,225.00 11,657.00
Abegg, Michael S. 000632024 2016 4,452.00 1,980.00 6,432.00 6,432.00
Abel, Elise C. 000716958 2016 4,452.00 1,980.00 6,432.00 5,125.00 4,000.00 15,557.00
Abell, Holly L. 000409543 2016 24,767.00 20,282.00 45,049.00 45,049.00
Abernathy, Joshua 000652600 2016 23,330.00 23,330.00 23,330.00
Abernathy, Kristia P. 000390040 2016 39,190.00 39,190.00 39,190.00
Aberra, Hanna D. 000481200 2016 3,401.00 693.00 4,094.00 2,888.00 6,982.00
Abijaoude, Melena A. 000471338 2016 5,442.00 1,980.00 7,422.00 5,325.00 4,000.00 16,747.00
Pivot table of data to left created by KPMG

Abioye, Alishka J. 000468279 2016 27,546.00 27,546.00 27,546.00
Abioye, Alishka J. 000468279 2017 21,083.00 14,987.00 36,070.00 36,070.00
Row Labels Sum of Total Direct Loan Sum of HRSAC Sum of PELL Sum of PERKINS Sum of SEOG
2012 - (525)
2014 (232)
2015 231,958 7,087
2016 110,969,197 199,669 6,248,839 1,426,066 976,519
2017 5,291,589
Grand Total 116,492,512 199,669 6,255,401 1,426,066 976,519
Data from pivot table above

Direct Loans
2012 - Goes to Tab 1
2014 (232) Goes to Tab 1
2015 231,958 Goes to Tab 1
2016 110,969,197 Goes to Tab 1
2017 5,291,589 Goes to Tab 1

Verify those totals by account number for the period, and submit the full report to the Research Accounting and Post-Award Group
in the Office of the Vice President for Research.

For OTHER LOAN TYPES remember that we add fiscal year expenditures (calculated as above) to the beginning balance from the
footnotes in the prior year report.
AS PROPOSED BY KPMG
FY16 beginning balance
(beginning balances come
from FY15 FN3 of Single 2016 Amount for
Grant/Program Title Audit Report) Advances 2016 ACA 2016 SEFA
Federal Perkins Loan Program 14,591,947 1,426,066 185,035 16,203,048
Loans for Disadvantaged Students 284,266 40,000 - 324,266
Nursing Student Loan Program 689,763 149,706 - 839,469
Primary Care Loans 2,973,442 - - 2,973,442
Nurse Faculty Loan Program 324,454 14,118 - 338,572
ARRA 28,638 - - 28,638
18,892,510
MDC-04182017

March 8, 2018
KPMG LLP
10 South Broadway
ASSOCIATE VICE
Suite 900
PRESIDENT FOR St Louis, MO 63102
RESEARCH
3700 West Pine Mall Ladies and Gentlemen:

Fusz Memorial Hall
Room 255 This is to document a correction plan for the 2017 Audit findings.
St. Louis, MO 63108
P 314-977-2047 Finding 2017-001 -- Inaccurate Reporting of Federal Expenditures on the Schedule of

F 314-977-2026
mchristian@slu.edu Expenditures of Federal Awards (SEFA)
www.slu.edu On an initial draft of the SEFA, KMPG found several items that were not correctly
classified under the R&D cluster. The University concurs that there was insufficient
supervisory review at the time the draft was produced.
The error on the draft version of the SEFA was the result of programming in the
software that formats the SEFA. Immediately after discovering the error, the University
made adjustments to the reporting tool that has eliminated the error. Going forward,
the University will add a manual check and supervisory review to the process, prior to
submitting the initial draft. Matthew Christian, Associate Vice President for Research
was responsible for ensuring that the software was correctly configured and a new
standard operating procedure document was written; he will be responsible for
ensuring that supervisory reviews are completed at the time the draft is run. The
corrective action is complete.
Finding 2017-002 -- Equipment & Real Property Management
KPMG found that one equipment asset was no longer a part of the University’s assets.
The University concurs with the finding.
The University will change its internal controls on annual physical inventory to require a
secondary verification of assets beginning with the 2018 physical inventory. The Office
of the Vice President for Research will implement the new control by April 30, 2018.
Matthew Christian, Associate Vice President for Research will be responsible for
implementing this corrective action.
Respectfully submitted,
Matthew Christian
Associate Vice President
Higher purpose. Greater good.

Consolidated Financial Statements June 30, 2017 and 2016 (With Independent Auditors' Report Thereon)

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Consolidated Financial Statements June 30, 2017 and 2016 (With Independent Auditors' Report Thereon)

Uploaded by

Copyright:

Available Formats

SAINT LOUIS UNIVERSITY

Consolidated Financial Statements

June 30, 2017 and 2016

(With Independent Auditors’ Report Thereon)

Assets 2017 2016

See Accompanying Notes to the Consolidated Financial Statements

Temporarily Permanently June 30, 2017

See Accompanying Notes to the Consolidated Financial Statements

Temporarily Permanently June 30, 2016

See Accompanying Notes to the Consolidated Financial Statements

(1) Summary of Significant Accounting Policies

(b) Presentation of Consolidated Financial Statements

(c) Tax Exempt Status

(d) Measure of Operations

(e) Use of Estimates

(f) Revenue Recognition

(g) Scholarship Allowances

(i) Auxiliary Enterprises Revenues

(j) Patient Care Revenues

Year ended June 30

(k) Nonoperating Activities

Year ended June 30

(l) Cash and Cash Equivalents

(m) Accounts Receivable, Net

June 30, 2016

As of June 30, the maturities of pledges were distributed as follows:

(n) Allowance for Doubtful Accounts – Patient Care

(p) Fair Value of Financial Instruments

(q) Derivative Financial Instruments

(r) Notes Receivable

1-60 Days 60-90 Days 90+ Days Total

(s) Unexpended Bond Proceeds

(u) Other Accrued Liabilities

(v) U.S. Government Refundable Grants

(w) Foreign Currency Translation

(x) New Accounting Pronouncements

(2) Third Party Reimbursed Health Programs

Year ended June 30, 2017

Year ended June 30, 2016

(4) Fair Value Measurements

(5) Land, Buildings and Equipment, net

Asset Retirement Obligation

(6) Debt Agreements

Twenty-five year Health and Educational Facilities Variable Rate Demand

Twenty-seven year Health and Educational Facilities Variable Rate Demand

NTCIC – Hotel Ignacio Project, LLC, note payable

SLH Vista, Inc., unsecured promissory note

(7) Lease Obligations

(8) Split-Interest Agreements

(9) Functional Expenses

Year ended June 30

(10) Restricted Net Assets

The University’s permanently restricted net assets are restricted to:

(11) Endowment Funds

1. The duration and preservation of the fund

(b) Endowment Spending Policy

(c) Endowment Investment Policy

(d) Endowment Funds with Deficiencies and Other Matters

June 30, 2016

(12) Insurance Programs

(13) Retirement Benefits

(14) Governmental Grants and Contracts